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Jessica Jean Howell, Ph.D.
The Rockefeller University 2009
The Forkhead box A2 transcription factor (Foxa2/HNF-3β) has been
shown to be a key regulator of genes involved in the maintenance of glucose
and lipid homeostasis in the liver, and is constitutively inactivated in several
hyperinsulinemic/obese mouse models, thereby enhancing their metabolic
phenotypes. Foxa2 is activated under fasting conditions, but is inhibited by
insulin signaling via PI3K/Akt in a phosphorylation-dependent manner, which
results in its nuclear exclusion.

However, the mechanism and relative

importance of nuclear export have not yet been elucidated. In addition, the
existence and potential role of insulin-dependent regulation of Foxa2 have not
been studied in other tissues where it is expressed, such as the gut, lung, and
hypothalamus.
Here we further investigate the regulation of Foxa2 by insulin and the
mechanism and relevance of its nuclear exclusion.

We demonstrate that

differential regulation of Foxa2 exists in different mouse models, that this
variability is dependent on circulating insulin levels, and that Foxa2 activity
correlates with metabolic function. We further show that Foxa2 contains a
functional nuclear export signal and is excluded from the nucleus via a CRM1-

dependent pathway in response to insulin signaling. Our data provide direct
evidence that nuclear export-defective Foxa2 is phosphorylated and inactivated
by insulin both in vitro and in vivo, suggesting that phosphorylation itself is the
main regulatory event regulating the activity of Foxa2, and not nuclear
exclusion per se. Finally, we provide evidence for and physiological
consequences of insulin-dependent inactivation of Foxa2 in two other
metabolic organs: the hypothalamus and the lung.
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INTRODUCTION
Globally, diabetes is ranked by the world health organization as the fifth
leading cause of death (1). Using data from 2003, the international diabetes
foundation estimated that 194 million people, ages 20-79 (roughly 5% of the
world’s population) have diabetes. An additional 8% show signs of impaired
glucose tolerance, a high risk factor for the development of type 2 diabetes (2).
With the death rate from diabetes mellitus having increased by 45% from 19872002, it is imperative that we understand the underlying causes of this complex
disorder (3).
Originally described as nonketotic, or non-insulin-dependent diabetes,
type 2 diabetes mellitus is a complex disease characterized by abnormal glucose
tolerance and hyperglycemia due to increased insulin resistance in combination
with relative insulin deficiency (4). While it has become clear that obesity (5, 6),
fat distribution (5), and physical inactivity (6) are all risk factors correlated with
the development of type 2 diabetes, the molecular mechanisms connecting
these risk factors to the onset of insulin resistance and relative insulin
deficiency resulting in type 2 diabetes remain unclear.
Understanding the pathology of diabetes requires an intricate knowledge
of the cellular signaling associated with insulin. In mammals, insulin is the
main hormone regulating the maintenance of glucose homeostasis. In fasting
states there exists a balance between glucose production and tissue uptake and
1

utilization, such that blood glucose levels are maintained within a narrow range.
In response to increased glucose levels, such as after a meal, insulin secreted
from pancreatic beta cells induces the uptake of glucose into peripheral tissues
and inhibits endogenous glucose production, thus restoring and maintaining
normoglycemia. Conversely, in fasting states when glucose and insulin levels
are low, and glucagon levels are increased, this suppression is relieved. (7)
The liver plays an essential role in this process of glucose homeostasis
and is a main target of insulin action. When insulin levels are high, hepatic
programs of gluconeogenesis, glycogenolysis and fatty acid beta oxidation are
suppressed (8). Though the effects of insulin are pleitropic and complex, this
suppression occurs in large part through the transcriptional inhibition of key
rate limiting enzymes in these pathways (9). To this end, the forkhead box A2
transcription factor (Foxa2/HNF3β) has been shown to be a key regulator of
genes involved in the maintenance of glucose and lipid homeostasis in the liver
(10, 11).
The forkhead superfamily of transcription factors, of which Foxa2 is a
member, is defined by a conserved, 110-amino acid winged-helix DNA binding
domain (12). Currently more than 100 members have been assigned to this
gene family in species ranging from yeast to humans (13). However, there is
very little sequence conservation outside of the winged helix domain in many
2

of these genes, where even subtle changes have been seen to affect DNA
binding (13, 14). Consequently the different forkhead family members have
been found to affect a varied array of target genes with functions ranging from
regulation of development in a wide variety of tissues (15, 16), to DNA repair
(17), and apoptosis (18). Some forkhead proteins have been shown to act as
transcriptional activators while others act as repressors.
The hepatocyte nuclear factor 3 (HNF-3)/forkhead family of
transcription factors in mammals includes three genes designated Foxa1 (HNF3α), Foxa2 (HNF-3β) and Foxa3 (HNF-3γ), which have overlapping patterns of
tissue expression, including gut, central nervous system, neuroendocrine cells,
and lung (14, 19). Originally identified as liver-enriched proteins that bind to
specific sequences in the transthyretin (TTR) and alpha1-antitrypsin (α1-AT)
promoters and activate their transcription (20), the HNF-3 (Foxa) proteins are
generally considered to be the founders of the forkhead family (identified at the
same time as the drosophila fork head protein) (14).
Foxa proteins have subsequently been shown to be critical regulators of
development, growth and metabolism in worms, flies and mammals. Reduced
levels of pha-4, the Foxa homologue in worms, leads to developmental arrest
and, post-embryonically, inhibits the ability of the organism to respond to
dietary manipulations (21). Simultaneous knock-down of daf-16, the Foxo
3

homologue, had an additive effect on dauer recovery in worms, suggesting that
these two factors function in parallel pathways.

Furthermore, dietary

restriction leads to increased expression of pha-4, which activates genes that
protect against oxidative damage (e.g. superoxide dismutase) (22).
Mouse genetic studies have also revealed important roles for murine
Foxa genes in development and metabolism. In livers of adult mice, Foxa2
activity has been shown to mediate fasting responses, including fatty acid
oxidation, ketogenesis, and increased VLDL and HDL secretion, by activating
gene expression of key enzymes of these pathways (10, 23, 24).
The DNA-binding domain of Foxa3 has been crystallized bound to its
target DNA sequence, revealing monomeric DNA-binding and a novel
“winged helix” motif (25). The extent and pattern of sequence conservation in
the DNA-binding regions of known members of the forkhead family indicates
that all forkhead family members share this basic structural domain.

In

particular, this is assumed to be the case for Foxa1 and Foxa2 which share 95%
and 90% sequence identity in this region, respectively.
Interestingly, it was also observed that this Foxa DNA binding domain is
similar in structure to that of the linker histone H5 (25). However, in contrast
to linker histones that compact DNA in chromatin and repress gene
expression, FoxA proteins are associated with transcriptionally active
chromatin and may decompact DNA from the nucleosome (26, 27).
4

Additionally, this high affinity DNA-binding site in combination with Cterminal regions mediating interaction with histones H3 and H4 have been
shown to enable Foxas to act as pioneer transcription factors, which are able to
decompact DNA from nucleosomes without ATP-dependent enzymes (26).
While Foxa proteins share very high sequence homology within the
DNA binding domain (as well as a suggested common consensus sequence for
DNA binding (28)), Foxa proteins are not entirely redundant in function.
Outside of this conserved region, Foxa1 and Foxa2 are only 39% identical,
with Foxa3 being even more distinct (14). Accordingly, these differences are
reflected in phenotypes of knock-out mice.

Mice homozygous for a null

mutation in Foxa2 exhibit an embryonic lethal phenotype, lack a notochord
and exhibit defects in foregut and neural tube development, while Foxa3deficient mice develop normally (29-31).

Mice lacking Foxa1 expression

develop neonatal persistent hypoglycemia, hormonal insufficiencies, pancreatic
alpha- and beta-cell dysfunction and die between postnatal days 2 and 14 (32,
33).
The sequence divergence among the Foxa proteins also allows for
unique posttranslational modifications and differential DNA and protein
interactions. Previous work in our lab has shown that Foxa2, but not Foxa1 or
Foxa3, is negatively regulated by insulin in the liver. In unstimulated, or fasting
states, Foxa2 is consistently observed in the nucleus, and only extensive
5

mutation of the DNA-binding/nuclear localization domains alters this cellular
distribution (10, 11, 19, 20, 34, 35).

However, in response to increasing

concentrations of insulin in vitro and in vivo in perfused mouse liver, Foxa2
shows dose-dependent nuclear exclusion, which corresponds with its
phosphorylation (10, 36). This phosphorylation has been mapped to threonine
156 in a conserved AKT site, and a single point mutation of T156 to alanine
(T156A) alone abolishes insulin-induced nuclear exclusion. Insulin has also
been shown to inhibit transactivation by Foxa2, both in reporter assays, as well
as in ad libitum fed and hyperinsulinemic mice. Likewise, this transcriptional
inactivation is completely alleviated by T156A mutation. Thus, Foxa2T156A is
a constitutively active, constitutively nuclear Foxa2 variant.
Cotransfection of wildtype or constitutively active (but not dominant
negative) AKT in reporter assays was shown to mimic the effects of insulin on
Foxa2 transactivation, while inhibition of PI3-kinase signaling repressed the
effects of insulin.

Direct phosphorylation of Foxa2 by AKT was further

supported by in vitro kinase assays,

in addition to coimmunoprecipitation

experiments, in which wildtype Foxa2, but not Foxa2 T156A or R153A (a
Foxa2 mutant that is unable to bind AKT) can be immunoprecipitated with
and phosphorylated by AKT (36, 37). Together these data have led to the
model proposed in Figure 1.
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Figure 1. Model illustrating the regulation of Foxa2 by insulin. Insulin binds to and activates the
insulin receptor (IR), which triggers autophosphorylation and the recruitment and phosphorylation of
insulin receptor substrate (IRS) adaptor proteins. These proteins transmit the insulin signal by
activating PI3-kinase, which phosphorylates phosphatidylinositol (4,5) bisphosphate (PIP2) and
catalyzes the formation of PIP3. This leads to the phosphorylation and activation of protein kinase B
(AKT) by PDK1 and the mTORC2 complex. AKT, which has been found in the nucleus upon
activation, phosphorylates Foxa2 at T156, which is then excluded from the nucleus and thus
inactivate. Insulin withdrawal allows reentry of Foxa2 into the nucleus, presumably through
regulation of a phosphatase.

Several studies have been carried out to elucidate the function of
different domains of Foxa2, and are summarized in Figure 2. In addition to its
winged helix DNA-binding domain, the regions flanking the C-terminal, and
partially overlapping the N-terminal end of this domain have been shown to be

7

required for nuclear localization. Four additional conserved regions have been
identified and together form two transactivation domains (at the amino and
carboxy terminal), which are important for target gene discrimination and
activation (34, 38). More recently the AKT phosphorylation site and a PGC1βinteraction domain have been described (24, 36).

Figure 2. Schematic depiction of Foxa2 showing known domains. II-V, transactivation domains; p,
phosphorylation site; NLS, nuclear localization signal (N- or C-terminal of the DNA binding
domain); DBD, DNA binding domain; PGC1β, PGC1β interaction domain.

The importance of the phosphorylation site has been further analyzed in
mouse models of type 2 diabetes. In hyperinsulinemic/obese mice, Foxa2 (but
not Foxo1) is permanently excluded from the nucleus and its inactivation
contributes to the development of hepatic steatosis and insulin resistance. This
has been demonstrated by re-expression of constitutive active Foxa2
(Foxa2T156A) in livers of obese mouse models that led to increased Fatty acid
oxidation, increased VLDL secretion, reduced hepatic TAG content and
increased insulin sensitivity and normalization of blood glucose levels (10).
The differential regulation of Foxo1 and Foxa2 in insulin resistant states
is somewhat counterintuitive, since both have been shown to be inhibited by
insulin signaling through the PI3-kinase pathway.

However, this can be

explained by increased sensitivity of Foxa2. Knockdown of IRS2 alone was
8

able to abolish nuclear export of Foxo1, however knockdown of both IRS1
and IRS2 was required for inhibition of nuclear export of Foxa2 (10). It has
been shown that there is decreased expression of IRS2 in insulin-resistance
states, while IRS1 levels remain unchanged (39).

This provides an enticing

explanation for the mixed insulin resistance observed in many models of type 2
diabetes,

and

suggests

a

mechanism

whereby

the

inhibition

of

gluoconeogenesis is lost, but the inhibition of fatty acid oxidation is not.
As evidenced by Foxo1, the negative regulation of forkhead
transcription factors by nutritional or stress signals is not unique to Foxa
proteins.

PI3-kinase/Akt signaling in the nematode Caenorhabditis elegans,

suppresses the function of DAF-16, a transcription factor that belongs to the
Foxo branch of the forkhead/winged-helix family (40). Mutations in the
insulin/Igf-1 receptor homologue (daf-2) (41, 42), the catalytic subunit of PI3kinase (age-1) (43), or Akt (akt1 and akt2) (44), result in increased longevity and
constitutive dauer formation, a stage of developmental arrest and reduced
metabolic activity that enhances survival during periods of food deprivation
and other environmental stresses. In each case, mutation of daf-16 restored
normal life span and prevented entry into dauer stage.
In mammals, this regulation has also been described for Fkhr (Foxo1),
Fkhrl1 (Foxo3), and AFX (Foxo4) (18, 45-47). Foxo-1 can be phosphorylated
by Pkb/Akt at multiple sites causing repression of transcriptional activity of
9

target genes such as insulin growth factor binding protein 1 (Igfbp-1), glucose6-phospatase and phosphoenolpyruvate carboxykinase (48, 49).

Similar to

Foxa2, this regulation has been shown to occur, at least in part, by nuclear
exclusion, although recent findings suggest that additional mechanisms are
involved (50). At the moment it is unclear whether nuclear export is the key
mechanism regulating Foxo transcription factors or whether other nucleus
specific regulatory pathways are involved in the regulation of this factor as well.
The constitutive inactivation of Foxa2 by insulin, in addition to the
beneficial effects of constitutively active Foxa2 in mouse models of obesity
make understanding the molecular mechanisms of its regulation of great
scientific and potentially therapeutic interest.

While it is clear that

phosphorylation is necessary for nuclear exclusion of Foxa2, the mechanism
and importance of nuclear exclusion in the inactivation of Foxa2 by insulin has
not previously been investigated. Here, we explore the molecular mechanisms
controlling nuclear exclusion of Foxa2 in response to insulin signaling, and its
physiological impact in the liver, lung and hypothalamus.
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CHAPTER 1: Genetic Strain variations modulate Foxa2 activity
1.1 Effect of insulin on Foxa2 in hepatocytes from diabetic mice
We have shown that nuclear exclusion of Foxa2 closely correlates with
insulin levels, both in wild-type C57Bl/6 and in hyperinsulinemic mouse
models.

Nonetheless, there was initially some disagreement in the literature

over this point (11). While wildtype C57Bl/6 mice have fasting glucose levels
around 0.3 ng/mL (going up to ~3 ng/mL in fed mice) ob/ob, db/db and HF
mice are all hyperinsulinemic even after a fast, with plasma insulin
concentrations ranging from ~5-80 ng/mL. To directly analyze the effects of
insulin on the nuclear exclusion of Foxa2, we isolated primary hepatocytes
from these mice and subjected them to controlled amounts of insulin.
As evidenced by quantitation of nuclear and cytoplasmic extracts, an
overnight “fast” (serum withdrawal) is sufficient to restore Foxa2 to the
nucleus of primary hepatocytes derived from different hyperinsulinemic mouse
models, when left untreated (Figure 3). This demonstrates that there is no
inherent/irreversible defect in these cells that results in nuclear exclusion of
Foxa2. Furthermore, Foxa2 is excluded from the nucleus and localizes to the
cytosol in a dose-dependent manner in response to insulin in all hepatocytes.
Thus, alterations in the insulin levels alone are sufficient to induce nuclear
inclusion or exclusion of Foxa2.
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Figure 3. Insulin-dependent Foxa2 localization in primary hepatocytes. Nuclear and cytoplasmic
extracts were prepared from primary hepatocytes of wild-type C57Bl/6, ob/ob, db/db, and HF dietinduced obese mice, which were incubated for 6 h in the presence of varying amounts of insulin.
Foxa2 was detected by immunoblotting, quantified by densitometry and normalized to -Tubulin.
Data are means ± SD, n=2.

Notably, while insulin removal completely restored Foxa2 to the nucleus
in hepatocytes of ob/ob, db/db and HF diet mice, higher concentrations of
insulin were needed to re-induce nuclear exclusion.

In hepatocytes from

wildtype C57Bl/6 mice, Foxa2 was already cytoplasmic at 1 ng/mL insulin.
However, this concentration of insulin results in only ~20-25% nuclear
exclusion in ob/ob, db/db and HF hepatocytes, demonstrating that their
hepatocytes do retain a low level of insulin resistance in culture.

1.2 Genetic strain variations affect metabolic parameters
Diabetic mouse models represent an extreme metabolic phenotype.
However, even wild-type strains have been shown to display differing
propensities for weight gain and development of features of the metabolic
12

syndrome. C57Bl/6 mice, for example, are more obese, glucose intolerant,
hyperinsulinemic, and hyperletpinemic than Sv129 mice on either regular chow
or a high-fat diet, and are more susceptible to the development of insulin
resistance and diabetes (51, 52). While these genetic discrepancies cannot be
traced to single genetic alterations, it has subsequently been found that
different strains have varying levels of circulating hormones such as insulin, and
exhibit different metabolic parameters (51-54).

Glucose (mg/dL)
Insulin (ng/mL)
Cholseterol
Triglycerides
Ketone bodies
Liver triglycerides
Glycogen

Sv129
fasted

Sv129
fed

CD1
fasted

CD1
fed

DBA
fasted

DBA
fed

C57Bl/6 C57Bl/6
fasted
fed

83 ± 9
0.14 ± 0.04
104 ± 10
104 ± 12
2.6 ± 0.2
19 ± 3
n.d

164 ± 11
0.31 ± 0.06
103 ± 13
102 ± 34
2.5 ± 0.2
20 ± 2
3.1 ± 0.4

90 ± 10
0.22 ± 0.05
106 ± 11
101 ± 11
2.4 ± 0.2
20 ± 2
n.d

171 ± 21
0.48 ± 0.07
104 ± 13
100 ± 33
2.6 ± 0.3
20 ± 2
3.5 ± .5

81 ± 7
0.25 ± 0.04
94 ± 13
99 ± 14
2.6 ± 0.2
22 ± 3
n.d

199 ± 21
0.63 ± 0.1
90 ± 11
99 ± 27
1.9 ± 0.2
25 ± 2
3.5 ± .6

100 ± 10
0.31 ± 0.05
92 ± 10
87 ± 13
2.5 ± 0.3
24 ± 2
n.d

255 ± 31
1.7 ± 0.12
80 ± 9
84 ± 31
1.3 ± 0.2
30 ± 2
3.3 ± .5

Table 1. Metabolic parameters of different mouse strains. Fasting and fed blood glucose, plasma
insulin, cholesterol, triglycerides and ketone bodies, liver triglycerides and glycogen were measured
from 6 male mice age 10-14 weeks. Data are means ± SD.

Initially we chose to investigate four different mouse strains: Sv129
(129), CD1, DBA, and C57Bl/6 (B6). As shown in Table 1, these mice exhibit
striking differences in their metabolic parameters, with 129 mice having the
lowest insulin levels, and B6 mice the highest. While B6 mice tended to have
lower circulating cholesterol and triglyceride levels in fasting and fed states,
these differences were not significant.

However, circulating ketone body

concentrations were significantly decreased in fed DBA and B6 mice, inversely
correlated to plasma insulin levels. Additionally, circulating ketone bodies were
significantly decreased in the fed state compared to the fasted state in DBA and
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B6 mice, while no significant differences between fed and fasted states were
observed in 129 or CD1 mice. We analyzed the rate of β-oxidation in livers of
these mice in fasted and fed states, and observed similar results. Both in the
fed and fasted state, DBA and B6 mice had the lowest rates of mitochondrial βoxidation, while 129 and CD1 animals exhibited the highest rates (Figure 4).
Furthermore, no change in rate was observed between fed and fasting states in
the latter two strains, while increased β-oxidation was observed in the fasted,
compared to the fed state of the DBA and B6 mice.

Figure 4. Fasting and fed β-oxidation rates varies between strains. Mitochondrial β-oxidation was
measured from livers as a function of 14CO2 production from [1-14]C-palmitic acid. n≥4.

1.3 Foxa2 and Foxo1 localization in different mouse strains
The differences in insulin levels, as well as the observed correlation with
the downstream regulation of β-oxidation and ketone body metabolism,
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encouraged us to analyze the nuclear localization of Foxo1 and Foxa2. These
two transcription factors have been shown to regulate metabolic genes and are
inhibited by insulin signaling in the liver. Foxa2, in particular, has been shown
to increase fatty acid oxidation and ketone body production, while Foxo1 is
preferentially involved in the activation of gluconeogenesis (10, 55).
Nuclear extracts were prepared from livers of mice from all four strains
(129, CD1, DBA, and B6), which were either ad libitum fed, fasted, or injected
with 10 ng/mL insulin through the portal vein. Western blotting of nuclear
fractions revealed that both Foxo1 and Foxa2 remain nuclear in fed and fasted
Sv129 and CD1 mice, while both are excluded from the nucleus in fed DBA
and B6 mice (Figure 5).
Furthermore, we could show that this is not an inherent defect in the
signaling ability or nuclear export mechanism in the livers of these mice, since a
bolus injection of insulin restored nuclear export of both Foxo1 and Foxa2.
Thus, insulin is able to enact nuclear exclusion of Foxo1 and Foxa2 to a similar
extent in livers of all four strains. This suggests that the differential regulation
observed in ad libitum fed states is a function of plasma insulin levels, which are
below the necessary threshold to achieve this effect, even in a fed state, in 129
and CD1 mice.
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Figure 5. Strain variation in nuclear localization of Foxa2 and Foxo1. Immunoblots of nuclear
extracts from livers of fasted, fed and fasted, insulin-injected Sv129, C57Bl/6, CD1, and DBA mice.

1.4 Decreased insulin signaling, but increased sensitivity in Sv129 and
CD1 mice
To determine the more general hepatic effects of different circulating
concentrations of insulin in these strains, we perfused livers with increasing
amounts of insulin and analyzed insulin signaling pathways by western blotting
and RT-PCR. Total levels of insulin receptor (IR), insulin receptor stubstrates
1 and 2 (Irs-1, Irs-2) and Akt expression remained unchanged in all strains
during insulin perfusion, however we observed an increase in Akt
phosphorylation, as well as Mapk phosphorylation, in response to increasing
insulin concentration in the perfusate (Figure 6). Accordingly, decreased levels
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of nuclear Foxa2 and Foxo1 were observed in all strains with increasing
concentrations of insulin. RT-PCR analysis revealed that the expression of
downstream target genes of Foxa2 and Foxo1 is also inhibited by insulin
(Figure 7).
As a functional readout we measured β-oxidation and ketone body
production in the livers of these mice. Again, insulin resulted in decreased βoxidation and ketone body production in all strains in a dose-dependent
manner (Figure 8). Notably, 129 and CD1 strains were even more insulin
sensitive, showing earlier activation of insulin signaling pathways and greater
levels of target gene suppression at lower concentrations of insulin. This
suggests that the altered metabolic rates observed between these strains are
directly correlated to plasma insulin levels, insulin signaling and Foxa2 and
Foxo1 localization.
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Figure 6. Insulin perfusion shows strain variations in insulin signaling. Livers from B6, 129, DBA and
CD1 mice were perfused with increasing concentrations of insulin and activation of insulin signaling
pathways was analyzed by immunoblotting whole cell or nuclear (n) lysates. TBP, Tata-binding
protein; p, phopsho.

18

Figure 7. Strain variation in repression of metabolic genes by insulin. RT-PCR from livers of B6, 129,
DBA and CD1 mice perfused with increasing concentrations of insulin. Pepck, Phosphoenolpyruvate
carboxykinase;
CptI, Carnitine palmitoyltransferase 1; Mcad, Medium chain acetyl-coA
dehydrogenase; b-DH, 3-Hydroxybutyrate dehydrogenase; Acet, Acetyl-CoA Synthase; Mtp,
Microsomal triglcyeride transfer protein.

19

Figure 8. Strain variations in ketone body production and β-oxidation in response to insulin. Ketone
body production and mitochondrial β-oxidation were measured from livers as a function of 14CO2
production and 14C- acid-soluble products, respectively, from [1-14]C-palmitic acid. n≥4.

1.5 Constitutive activation of Foxa2 increases hepatic lipid metabolism
in livers of Fed C57Bl/6 mice
To more directly determine what effect the amount of active/nuclear
Foxa2 has on the observed metabolic discrepancies in these mouse strains, we
injected ad libitum fed Sv129 and C57Bl/6 mice with constitutively active Foxa2
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(T156A) adenovirus. As shown in Figure 9, cellular fractionation confirmed
that endogenous Foxa2 is nuclear in livers of 129 mice, but cytoplasmic in
livers of B6 control mice injected with GFP adenovirus.

Adenovirally

expressed Foxa2-T156A is constitutively nuclear in livers of both strains.

Figure 9. Localization of Foxa2 and Foxa2-T156A in livers of 129 and B6 mice. 129 and B6 were
injected with 1E9 PFU of GFP or Foxa2-T156A adenovirus. Six days post injection, mice were
sacrificed, livers were fractionated, and nuclear and cytoplasmic extracts were analyzed for Foxa2
localization by western blotting.

As shown in (Figure 10), expression of constitutive active Foxa2 leads to
a significant increase in mitochondrial β-oxidation in B6 mice, where
endogenous Foxa2 is inactive. Conversely, the effect of Foxa2-T156A is not
significant in 129 animals, which already have active Foxa2 in the nucleus.

Figure 10. Activation of Foxa2 restores βoxidation in livers of Fed B6 mice.
Mitochondrial β-oxidation measured in 129
and B6 mice six days post injection with
either Ad-GFP or constitutively active (AdT156A) Foxa2. Data are means ± SD, n≥4.
** , p<0.01 by students t-test.
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RT-PCR reveals a similar trend in expression of genes involved in βoxidation and ketone body synthesis.

Foxa2-T156A results in significant

upregulation of CptI, Mcad, Vlcad, and b-DH in B6 mice, compared to GFP
controls, while Pepck gene expression (encoding the rate-limiting enzyme for
heptatic gluconeogenesis) is unchanged (Figure 11).

Foxa2-T156A also

increases expression of these genes in Sv129 mice, however to a lesser extent,
and only Cpt is significantly upregulated.

Figure 11. T156A-Foxa2 re-activates expression of B-oxidation genes in the liver. Relative expression
levels of genes involved in B-oxidation, ketone body synthesis and gluconeogenesis were analyzed by
real time PCR from livers of 129 or B6 mice adenovirally expressing GFP or Foxa2-T156A (T156).
Data are means ± SD, n≥4.

1.6 Summary
These studies demonstrate that genetic strain variations, in mice as in
humans, play an important role in determining metabolic phenotypes. Here we
show that nuclear localization of Foxa2 (and Foxo1) correlates with
physiological insulin levels in four different mouse strains. Sv129 and CD1
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mice, which have low physiological levels of insulin, retain Foxa2 in the nucleus
even in fed states. DBA and C57Bl/6 mice have higher insulin levels, which
are sufficient to induce nuclear export and inactivation of Foxa2 in the fed
state. This data also provides a possible explanation for the lack of Foxa2
shuttling observed by Zhang and colleagues (11). Interestingly, constitutive
activation of Foxa2 in livers of fed B6 mice is sufficient to restore
mitochondrial β-oxidation to fasting levels, similar to fed Sv129 mice, and
suggests that the differential regulation of Foxa2 plays a major role in liver lipid
metabolism, and the metabolic phenotype.
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CHAPTER 2: Shuttling of Tagged Foxa2
2.1 Functional analysis of the Foxa2 Akt phosphorylation site
We have shown that Akt phosphorylation of Foxa2 at T165 mediates its
nuclear exclusion and transcriptional inactivation in response to insulin;
however the mechanisms involved in this regulation remain unclear. It has
been observed that the Foxa2 Akt site (RRSYTH) does not perfectly match the
canonical Akt recognition motif (RARSYS/TH), yet it is evolutionarily
conserved in Foxa2. To attempt to address whether this imperfection has
some additional significance in the regulation of Foxa2, we generated two
variants with canonical Akt sites: Foxa2-pAins was generated by inserting an
additional alanine after R152, while Foxa2-pMut was generated by mutating
Y151R and R152A. In reporter assays both Foxa2-pAins, and Foxa2-pMut
showed similar transactivation levels to wildtype Foxa2 under basal conditions,

Figure 12. Transactivation of Foxa2
Akt site variants. HepG2 cells were
transfected with expression vectors
containing Foxa2 or variants, alone or
in combination with DN-Akt or Akt2.
p6xCdx-TkLuc was used as a reporter
gene, normalized to renilla luciferase,
and shown relative to vector only
controls.
Experiments
were
performed in triplicate and are
representative of 2 independent
experiments.
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similar increases when coexpressed with dominant negative Akt (DN-Akt), and
all were repressed to a similar degree by coexpression of wildtype Akt (Figure
12). Thus, it appears that the exact sequence of this Akt site is not essential for
the regulation of Foxa2 by Akt. Nonetheless, we cannot rule out that alteration
of this site might have a more subtle effect in vivo that was not observed in an in
vitro analysis requiring cellular manipulation and overexpression.
To further investigate the importance of this phosphorylation site we
took advantage of the fact that Foxa1, a highly homologous member of the
Foxa family, does not shuttle in response to insulin. Additionally, sequence
alignment of these two proteins revealed that Foxa1 has a T->P substitution in
the region corresponding to the Akt phosphorylation site in Foxa2 (alignment
of this region is shown in Figure 13.)

Figure 13. Partial sequence alignment of Foxa1 and Foxa2. The Foxa2 Akt phosphorylation site, is
highlighted in yellow.

We therefore asked whether introduction of the Foxa2 Akt site into
Foxa1 would be sufficient to induce its inactivation by insulin. This approach
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has been successfully used to identify a PGC1βinteraction domain in Foxa2, and has also been
used to demonstrate the importance of a
Figure 14. Expression of Foxa1
mutants. Whole Cell extracts
from HepG2 cells transfected
with pcHAFoxa1 or
pcHAFoxa2p3B, detected with
an α-HA antibody

phosphorylation motif for shuttling of Foxo3 by
domain swapping with Foxo6 (24, 56). Site directed

mutagenesis was performed to clone the Foxa2 Akt site into a plasmid
containing HA-tagged Foxa1 (Foxa1p3B), replacing the corresponding region
in Foxa1, and its expression was confirmed by sequencing and western blot
analysis (Figure 14).
To test whether introduction of the phosphorylation site was sufficient
to induce Akt-dependent inhibition of Foxa1, expression vectors for Foxa1,
Akt2, or dominant negative Akt (DN-Akt) were coexpressed with
pGL2hGlucP, a luciferase reporter plasmid containing the human glucagon

Figure 15. Transactivation by Foxa1 and Foxa1p3B. HepG2 cells were transfected with expression
vectors containing Foxa1 constructs, alone or in combination with DN-Akt or Akt2. pGL2hGlucP
was used as a reporter gene. Firefly luciferase activity was normalized to renilla luciferase, and
shown relative to vector only controls. Experiments were performed in triplicate and shown as the
average of 3 independent experiments ± SEM.
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promoter (shown to preferentially bind Foxa1(57)) upstream of a minimal
promoter and the firefly luciferase gene. Both Foxa1 variants only weakly
transactivate the reporter, however there was no significant difference observed
between them, with or without cotransfection of Akt or DN-Akt (Figure 15).
If anything, transcriptional activity was stimulated by Akt, although this could
be a general effect of increased transcription/translation caused by mimicking
activation of a growth factor signaling pathway.
Foxa2 transactivation, as has been previously shown (36), was enhanced
by co-expression with dominant negative Akt, and inhibited by overexpression
of wild-type Akt2 in parallel experiments (Figure 16). These data suggest that
the Foxa2 phosphorylation site alone is not sufficient to induce nuclear
exclusion by Akt, and demonstrate that additional sequence elements might be
necessary for the insulin-induced nuclear exclusion of Foxa2.

Figure 16. Foxa2 transactivation is inhibited
by Akt. HepG2 cells were transfected with
expression vectors containing Foxa2, alone
or in combination with DN-Akt or Akt2.
p6xCdx-TkLuc was used as a reporter gene.
Firefly luciferase activity was normalized to
renilla luciferase, and shown relative to
vector only controls. Experiments were
performed in triplicate and shown as the
average of 3 independent experiments ±
SEM.
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2.2 Transient transfection inhibits shuttling of Foxa2
To further elucidate the sequence elements responsible for the insulininduced nuclear exclusion of Foxa2 we generated N- and C-terminal Foxa2GFP fusion constructs (GFPN1- and GFPC1-Foxa2, respectively). This is a
useful approach for studying the intracellular
localization of proteins in real time and in live cells,
and has been previously used to visualize the
intracellular localization of many different proteins,
Figure 17.
Expression of
Foxa2-GFP fusion proteins.
Whole cell lysates from HepG2
cells transfected with the
indicated
GFP-Foxa2
expression plasmids, separated
by SDS-PAGE and subject to
western blot analysis.

including members of the Foxo family, which also
shuttle in response to external stimuli (56, 58-60).
Western blot analysis confirmed the expression of a
~90 kDa band corresponding to the predicted size

of GFP-Foxa2 fusions (Figure 17).

However, fluorescence microscopy

revealed that GFPC1-Foxa2 transfected into HepG2 cells was constitutively
nuclear, despite cotransfection with Akt (Figure 18). Insulin was also unable to

Figure 18. Immunofluorescent localization of GFPC1-Foxa2. HepG2 cells were
transfected with 20ng of pEGFP-C1 (Clontech) or GFPC1-Foxa2, with or without
cotransfection of Akt2 (40ng), and detected by fluorescence microscopy.
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alter this nuclear localization, and GFPN1-Foxa2 gave similar results, with or
without insulin or cotransfection of Akt (data not shown).
To determine whether this effect might be due to transient transfection,
we analyzed the localization of HA and FLAG double-tagged wildtype rat
Foxa2 (HA-Foxa2, which has previously been shown to shuttle in response to
insulin signaling (36)) after transfection into HepG2 cells. Once again, even
after stimulation with 500 nM insulin Foxa2 remained nuclear (Figure 19).

Figure 19. Immunofluorescence localization of transfected Foxa2. HepG2 cells were
transiently transfected with 20ng of HA-Foxa2, serum starved for 18 hours and treated
with or without 500nM insulin for 20minutes. Cells were fixed and stained with antiHA antibody overnight at 4° and visualized with Alexa 480 Goat anti-mouse IgG using
laser scanning micrsocopy. Nuclei were visualized by costaining with Topro3.
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2.3 Cytoplasmic relocalization of endogenous Foxa2 by cellular
fractionation
Given these unexpected in vitro results and the emerging controversy
over Foxa2 shuttling, we decided to reconfirm nuclear exclusion of Foxa2 in
vivo, using previously established methods. Nuclei were extracted from livers
of fasted, random fed and ob/ob mice and assayed for the presence or absence
of Foxa2 by western blotting. As shown in Figure 20, Foxa2 was found in the
nuclear fractions of livers of fasted mice, but was excluded in the livers of
random fed and ob/ob mice. Additionally, fasted mice injected with 150 ng of
insulin 15 min prior to sacrifice showed nuclear exclusion of Foxa2, while PBSinjected mice did not (Figure 21).
Figure 20. Nuclear exclusion of Foxa2 in livers of fed and
hyperinsulinemic mice. Immunoblot analysis of Foxa2 in
nuclear extracts from livers of C57BL/6 and ob/ob mice,
fasted for 24 h or ad libitum fed. Nuclear extracts were
prepared by sucrose gradient fractionation and each lane
represents livers pooled from 2 mice.

Figure 21. Nuclear exclusion of Foxa2 is
Immunoblot
induced by insulin in vivo.
analysis of Foxa2 in nuclear extracts from livers
of C57BL/6 mice, fasted for 24 h and injected
with PBS or 600 ng insulin via the tail vein.
Nuclear extracts were prepared by sucrose
gradient fractionation. The upper band is nonspecific and serves as an internal loading
control.
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While these data demonstrate robust nuclear exclusion of Foxa2, thereby
confirming previous results, the experimental protocol did not allow for
simultaneous analysis of cytoplasmic fractions, an ideal internal control. We
therefore sought to develop a robust assay for determining the cellular
localization of this factor both in vitro and in vivo. We subsequently used a
gentle hypotonic lysis buffer to release cytoplasmic proteins, followed by brief
centrifugation to pellet nuclei, which were ultimately extracted by addition of
ammonium sulfate to 400 mM. This method of cellular fractionation yielded
good resolution of nuclear and cytoplasmic fractions in liver tissue, as indicated
by the predominantly nuclear localization of the TAF100 transcription factor
(Figure 22). Moreover, it allowed us to visualize not only the nuclear exclusion
of Foxa2, but the corresponding cytoplasmic relocalization upon stimulation
with insulin (and in hyperinsulinemic ob/ob mice) by cellular fractionation and
immunoblotting. This, in addition to the development of two new polyclonal
Foxa2 antibodies, greatly improved our ability to accurately assay the cellular
localization of Foxa2.
Figure 22. Cytoplasmic localization of
Foxa2 in livers of insulin-injected and
hyperinsulinemic
mice.
Nuclear/cytoplasmic fractionation of
50 mg of frozen liver from fasted mice
injected with either PBS or insulin and
subject to immunoblotting.
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This new protocol allowed us to revisit the impaired shuttling of
transfected Foxa2. Nuclear and cytoplasmic extracts confirmed shuttling of
endogenous Foxa2 in untransfected HepG2 cells after stimulation with insulin,
verifying that Foxa2 also shuttles in vitro (Figure 23, null). However, after
transfection of the cells with either PCDNA3 vector and GFP, or HA-Foxa2
and GFP, neither transfected HA-Foxa2 nor endogenous Foxa2 shuttled in
response to insulin (Figure 23).

Figure 23. Endogenous and HA-Foxa2 are nuclear after transfection. HepG2 cells were transfected
with either GFP and pcDNA3 (GFP), or GFP and HA-Foxa2 (HAFoxa2), not transfected (null) or
mock transfected with Fugene only, serum starved for 19 h and treated with or without 500 nM insulin
for 15 min. Cellular fractionation was followed by SDS-PAGE and immunoblot analysis using the
indicated antibodies.

Mock transfection of the cells with Fugene transfection reagent did not
alter the shuttling of endogenous Foxa2, demonstrating that this is not strictly
an issue of toxicity caused by the transfection reagent. The same nuclear
phenotype was observed when we transfected different concentrations of
GFPC1-Foxa2 (Figure 24).
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Figure 24. GFPC1-Foxa2 is nuclear after transfection. HepG2 cells were transfected with
either 4 or 12 ug of GFPC1-Foxa2, or untransfected (null), serum starved for 19 h and treated
with or without 500 nM insulin for 15 min. Cellular fractionation was followed by SDSPAGE and immunoblot analysis with anti-Foxa2 antibody.

2.4 Nuclear/Cytoplasmic shuttling of tagged Foxa2
To avoid the issue of altered protein regulation after transfection, we
generated stable cell lines expressing N- and C-terminal GFP-Foxa2 fusion
plasmids in HepG2 cells. In the process of selecting stable cell lines we found
that GFP-Foxa2 fusions occasionally integrated in such a way as to cause
truncation of the fusion product. Clonal populations were selected based on
fluorescence, and fusion constructs were detected by immunoblot analysis of
whole cell extracts using an anti-HA antibody (Figure 25). Therefore, the
truncations were generally predicted to have been shortened from the Cterminus, with the exception of GFPN1-Foxa2 clone #2, which is around 50
kDa and appears to have retained both the N-terminal HA-tag and C-terminal
GFP.
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Figure 25. Stable expression of GFP-Foxa2 fusion constructs. Clonal populations of HepG2 cells
were selected for G418 resistance and fluorescence, and screened for expression of GFP-Foxa2
fusion products in whole cell extracts by immunoblotting with anti-HA and anti-GFP antibodies

Figure 26. Impaired shuttling of GFP-Foxa2 in stable cell lines. Immunoblots of nuclear and
cytoplasmic extracts from HepG2 cells stably expressing GFPC1-Foxa2, GFPN1-Foxa2, or truncations
thereof, with and without stimulation with 500nM insulin for 15min. HA antibody was used to
identify stably expressed Foxa2 variants, Foxa2 antibody was used to assay endogenous Foxa2, and γTubulin was used as a loading control.

Although we did not sequence the constructs to determine exactly where
truncations occurred, we took advantage of their size differences to investigate
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the shuttling properties of shortened fusions alongside the full-length
constructs. This allowed us to simultaneously assess whether stable expression
and/or total size reduction could enable shuttling of GFP-Foxa2. GFPC1Foxa2 #17, which is around 37 kDa and presumably contains less than 10 kDa
of Foxa2, was the smallest fusion protein generated. While this one did show a
general cytoplasmic shift in its distribution, the rest of the fusion constructs
remained nuclear, and none were excluded from the nucleus after stimulation
of the cells with insulin (Figure 26). Endogenous Foxa2, on the other hand,
shuttled to the cytoplasm in all GFPC1-Foxa2 stable cell lines, suggesting that
the loss of nuclear export observed with the GFP fusion constructs is not due
to decreased insulin sensitivity, but rather is an artifact caused by fusion to
GFP.
To further ensure that this was not
an in vitro issue, we generated adenovirus
from the GFPC1-Foxa2 construct and
injected this into wildtype mice.
Figure 27.
AdGFPC1-Foxa2 remains
constitutively nuclear in fasted and fed mice.
Immunoblots showing cellular fractionation
of livers from fasted or ad libitum fed
C57Bl/6 mice injected with GFPC1-Foxa2
adenovirus.

Once

again, the GFPC1-Foxa2 construct was
clearly nuclear in livers from both fasted
and fed mice (Figure 27). Taken together,

these data demonstrate that both transfection and GFP-fusion inhibit insulininduced nuclear exclusion of Foxa2.
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As opposed to GFP, which encodes a protein of roughly 30 kDa, HA
and FLAG peptides are hydrophilic and immunogenic fusion tags that are
specifically designed to facilitate purification and detection using monoclonal
antibodies. Due to their small size, they are less likely to interfere with protein
function (61). We therefore established stable cell lines expressing N-terminal
HA and FLAG double-tagged Foxa2 (HA-Foxa2) in HepG2 cells. Indeed,
cellular fractionation showed that stably expressed HA-Foxa2 was almost
completely excluded from the nucleus (and relocated to the cytoplasm) by 15
minutes after stimulation with insulin in each cell line (Figure 28).

Figure 28. Nuclear-ctyosolic shuttling of HA-Foxa2 in vitro. Nuclear and cytoplasmic fractionation
of HepG2 cells stably expressing HA-Foxa2 (3B4, 3B6, 3B10 denote individual clones), with and
without stimulation with 500nM insulin for 15min. LSD1, and GAPDH were used as nuclear and
cytoplasmic loading control markers, respectively.

2.5 Summary
Here we show that Foxa2 shuttling is disrupted by transient transfection
in HepG2 cells in vitro. We have also tested shuttling in HEK293, and Huh7
cells, using various transfection methods with similar results (data not shown).
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While we were not able to elucidate the cause of this impaired shuttling, our
data suggest that it is a consequence of the transfection procedure. We have
further shown that GFP fusion to Foxa2 ablates its nuclear export. This effect
is independent of transfection, as we achieved the same results in stable cell
lines, and by adenoviral expression in vivo.
Previously shuttling of Foxa2 had only been observed by its absence in
nuclear extracts, or by immunofluorescent staining. Here we demonstrate the
nuclear exclusion and cytoplasmic relocalization of Foxa2 by cellular
fractionation, both in vitro and in vivo. Finally, we show that Foxa2 shuttling is
not disturbed by HA/FLAG epitope tagging, thereby confirming previous data
in the lab and establishing more robust assays for further mechanist analysis of
its regulation.
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CHAPTER 3: Nuclear export-independent inhibition of Foxa2
3.1 Foxa2 Contains a Nuclear Export Sequence
To identify possible mechanisms responsible for the nuclear export of
Foxa2 we used a candidate approach focusing on CRM1 (also called
exportin1/Xpo1) as the most common nuclear export factor. Since CRM1
mediated nuclear export can be potently inhibited by the pharmacological agent
leptomycin B (LMB) (62, 63) we used this to analyze CRM1-dependent
shuttling of Foxa2 in the 3B10 HepG2 cell line stably expressing HA-Foxa2
(3B10, Figure 31). Analysis of nuclear and cytoplasmic extracts showed that
LMB prevents the export of Foxa2 from the nucleus after stimulation with
insulin, while untreated control cells display normal export dynamics (Figure
29). This finding demonstrates that nuclear export of Foxa2 is mediated by
CRM1.

Figure 29. LMB inhibits nuclear export of Foxa2. Cellular fractionation of HepG2 cells stably
expressing HA-tagged Foxa2, serum-starved overnight and stimulated with 500nM insulin, with or
without pretreatment with 2.5ng/mL LMB. Foxa2 localization was determined by western blotting.
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To identify possible regulatory sites in Foxa2 we performed a
comparative analysis of the primary amino acid sequence using the generally
accepted CRM1 consensus sequence, LX(2,3)[LIVFM]X(2,3)LX[LI] (62, 64).
Interestingly, Foxa2 contains one leucine-rich sequence that closely resembles
this consensus nuclear export signal (NES) as shown in Figure 30, aligned to
the prototypical HIV-REV NES. This region lies in the N-terminal half of
Foxa2, about 40 amino acids upstream of the Akt phosphorylation site (T156),
between the transactivation and DNA binding domains, and is evolutionarily
well-conserved (Figure 30 and Figure 31).

Figure 30. Partial sequence alignment of Foxa2 from six different species, and the HIV-REV NES.
The putative NES (red) and phosphorylated threonine (blue) are highlighted. H, human; R, rat; M,
mouse; C, chicken; Xl, Xenopus laevis; Dm, Drosophila melanogaster.

Figure 31. Schematic depiction of Foxa2 showing the putative NES in relation to other known
domains, along with mutant constructs. II-V, transactivation domains; NES, nuclear export signal; p,
phosphorylation site; NLS, nuclear localization signal (N- or C-terminal of the DNA binding
domain); DBD, DNA binding domain; PGC1β, PGC1β interaction domain; Foxa2, rat wildtype Foxa2;
T156A, mutated at residue T156A; Emut, mutated at residues L110A and L113A; TAE, mutated at
residues T156A, L110A, and L113A.
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3.2 Foxa2 NES is Necessary for Nuclear Export
To elucidate whether the putative CRM1 NES is responsible for nuclear
export of Foxa2, and thus important for its regulation in different physiological
states, we performed mutational analyses. Since the C-terminal hydrophobic
residues of the CRM1 consensus sequence have been shown to be the most
critical for nuclear export (65), we mutated both terminal leucines (L110 and
L113) of the putative Foxa2 NES to determine whether this sequence is
necessary for nuclear exclusion in response to insulin. L110A, L113A Foxa2
(Emut, Figure 31) was stably expressed in HepG2 cells, and analyzed for its
ability to shuttle from the nucleus in response to insulin stimulation.
Endogenous Foxa2 was used as an internal control. We show that while
endogenous Foxa2 still shuttles in
these cells in response to insulin
stimulation,

the

export

mutant

remains nuclear, demonstrating that
the NES is functional and necessary
for export in vitro (Figure 32).
To test whether this sequence is
also necessary for export in vivo and
thus might play an important role in the
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Figure 32. Nuclear/cytoplasmic shuttling of
Foxa2 Emut in vitro. Immunoblots showing
cellular fractionation of HepG2 cells stably
expressing Emut Foxa2, serum-starved
overnight and stimulated with 500nM insulin.
γ-Tubulin was used as a general loading
control, and LSD1 and GAPDH served as
nuclear and cytoplasmic extraction controls,
respectively.

hormonal regulation of Foxa2 activity we generated a recombinant adenovirus
containing export mutant (Ad-Emut) Foxa2 and injected it into C57Bl/6 mice.
As controls we treated mice with recombinant adenoviruses expressing
wildtype (Ad-Foxa2) or phosphorylation-deficient, constitutively active Foxa2
(Ad-T156A), which have been previously characterized (10). All constructs
were HA- and FLAG-tagged, and GFP adenovirus was used as an additional
control. As shown in Figure 33, both endogenous and exogenous Foxa2 were
nuclear in all fasted animals. However, while endogenous and Ad-Foxa2 were
excluded from the nucleus in random fed animals, the export mutant (as well as
the T156A control) remained nuclear. Thus, the newly identified NES in
Foxa2 is responsible for the active nuclear export of Foxa2 in hepatotcytes
both in vitro and in vivo.

Figure 33. Ad-Emut is deficient in nuclear export in vivo. Immunoblots showing cellular
fractionation of livers from C57BL/6 mice infected with GFP, Foxa2, T156A, or Emut adenovirus.
Five days post-infection, mice were either fasted for 18 h (S) or ad libitum fed (F).
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3.3 Emut Foxa2 is inhibited by insulin signaling
The ability to study the effect of phosphorylation uncoupled from
subcellular localization of Foxa2 led us to ask whether regulation of Foxa2
activity by insulin is mainly controlled by nuclear export or by phosphorylation
at T156. To explore this latter possibility, we first sought to determine if Emut
Foxa2 could be efficiently phosphorylated through insulin signaling. Primary
hepatocytes were isolated from C57Bl/6 mice, infected with the corresponding
adenoviruses and serum starved overnight, followed by a 15 minute incubation
with insulin. Exogenous Foxa2 was immunoprecipitated and subjected to
western blot analysis with an anti-Foxa2T156-specific phosphopeptide
antibody. Western blots show that Emut Foxa2 is phosphorylated to a similar
extent as wildtype Foxa2, suggesting a segregation of postranslational
modification and cellular localization.
To further clarify this point we generated recombinant adenovirus
expressing a double Foxa2 mutant protein (TAE, Figure 31), containing both
the Emut and T156A mutations. The T156A and TAE mutants, both of which
lack the phosphorylation site and thus serve as negative controls, are not
detected by the phospho-specific antibody (Figure 34).
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Figure 34. Insulin results in phosphorylation of Emut Foxa2. Primary hepatocytes isolated from
C57BL/6 mice were infected with the indicated adenovirus, serum starved overnight and stimulated
with 100nM insulin. Whole cell extracts were subject to immunoprecipitation using an anti-HA
antibody. Immunoblots of whole cell extracts and IPs were probed with antibodies against HA and
phospho-Foxa2 (P-Foxa2).

Since the export mutant is phosphorylated in response to insulin
signaling, we hypothesized that, despite its nuclear localization, Foxa2 could
still be inactivated by its Akt dependent phosphorylation.

To test this

hypothesis, we first expressed wildtype Foxa2, T156A, or Emut plasmids
together with a reporter plasmid containing six Foxa binding sites of the
murine Cdx-2 gene upstream of firefly luciferase (6xCdx), with or without Akt2,
in HepG2 cells. Reporter assays showed that while the export mutant retained
transcriptional activity under basal conditions, cotransfection with Akt ablated
this activity to a similar extent as wildtype (Figure 35).

As a control,

Foxa2T156A remained fully active with or without Akt coexpression. These
data clearly demonstrate that on a functional level Foxa2 transcriptional activity
is primarily regulated by posttranslational modification rather than by nuclear
localization.
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Figure 35. Akt inhibits transactiation by Emut Foxa2. HepG2 cells were transfected with expression
vectors containing Foxa2 constructs, alone or in combination with Akt2. p6xCdx-TkLuc was used as
a reporter gene. Luciferase activity was normalized to renilla luciferase, and shown relative to vector
only controls. All experiments were performed in triplicate and values shown represent the mean of
three independent experiments ± SEM. *, p< .05; **, p<.01 by unpaired t-test.

To test whether these functional changes translate to the binding of
Foxa2

to

its

target

promoter

regions,

we

performed

chromatin

immunoprecipitations from C57Bl/6-derived primary hepatocytes infected
with Ad-GFP, Ad-Foxa2, Ad-T156A, Ad-Emut and Ad-TAEmut. In a serumstarved state, all Foxa2 constructs were able to bind to known Foxa2
interaction sites in CPT1, HMGCS, and L-PK genes. However, after insulin
stimulation, the wildtype and export mutant constructs were no longer found
to bind the target sites, while binding of the T156A and TAE mutant Foxa2
proteins was unaffected by insulin (Figure 36). These data confirm the results
obtained from the transactivation assays and show that phosphorylation
determines binding of Foxa2 to its responsive promoter elements and that
cellular localization is a secondary effect.
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Figure 36.
Insulin signaling disrupts promoter binding of Emut Foxa2.
Chromatin
immunoprecipitations from serum-starved or insulin-stimulated primary hepatocytes that were
infected with the indicated adenoviruses. Chromatin was immunoprecipitated with HA or IgG
(control) antibodies. Binding of Foxa2 and mutants to promoter sites in target genes was assayed by
PCR. CPT1, carnitine palmitoyltransferase 1; HMGCS, HMG CoA synthase; L-PK, liver pyruvate
kinase.

3.4 Emut is constitutively nuclear but inactive in hyperinsulinemic

ob/ob mice
The effect of constitutive activation of Foxa2 is most striking in
hyperinsulinemic mouse models that show constitutive inactivation of
endogenous Foxa2 (10). Thus, to assess the importance of nuclear export on
the physiological activity of Foxa2 in the context of metabolic disorders, and to
elucidate whether the biological activities of Foxa2 mutants show the same
regulation in vivo, we expressed Emut Foxa2 in the livers of ob/ob mice using
recombinant adenoviruses. Transcriptional activity, and resulting metabolic
and physiological consequences, were compared to age and sex-matched ob/ob
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mice injected with either wildtype, T156A, or TAE Foxa2 adenoviruses. We
previously demonstrated that endogenous and Ad-Foxa2 are constitutively
cytoplasmic and inactive in hyperinsulinemic mouse models of type 2 diabetes,
while Ad-T156A remains in the nucleus and is able to restore Foxa2 activity
(10). Nuclear and cytoplasmic extracts from the livers of these mice confirmed
that endogenous and Ad-Foxa2 are constitutively cytoplasmic, while the AdT156A, Ad-Emut and Ad-TAE Foxa2 constructs remain in the nucleus (Figure
37). Immuno-fluorescence microscopy was also used to confirm these results
(Figure 38).

Figure 37. Emut is constitutively nuclear in ob/ob mice. Ob/ob mice were injected with the
indicated adenovirus and livers were analyzed 10 days post-injection by cellular fractionation and
immunoblotting. γ-Tubulin was used as a general loading control, and LSD1 (Lysine-specific
demythlase 1) and GAPDH served as nuclear and cytoplasmic extraction controls, respectively.

To analyze the activity of the export mutant in these mice, which is the
most important functional readout, we measured target gene activation by realtime PCR and assayed various metabolic parameters over 10 days.

As

expected, mRNA levels of Foxa2 target genes involved in mitochondrial fatty
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acid oxidation and ketone body formation (MCAD, VLCAD, CPT1α, and
HMGCS) were upregulated in livers of the T156A-injected mice, while no
significant change was observed in mice injected with wildtype Foxa2.
Consistent with our previous findings, Emut Foxa2 was unable to activate
transcription of target genes in these hyperinsulinemic mice, while the double
mutant TAE Foxa2 restored constitutive activation (Figure 39). As a control,
we checked Foxa2 mRNA levels, which were upregulated roughly 2-fold in all
mice, relative to Ad-GFP controls (Figure 40).

Figure 38. Immunofluorescence localization of Foxa2 variants in ob/ob liver. Ob/ob mice were
injected with the indicated adenovirus and livers were frozen in OCT 10 days post-injection.
Cryosections stained with anti-HA and Donkey anti-rabbit IgG Alexa Fluor 488 (Green) and Dapi
(red) were visualized by fluorescence microscopy.
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Figure 39. Mean mRNA levels of Foxa2
target genes in livers of ob/ob mice
injected with the indicated adenovirus,
n≥3. MCAD, medium chain acyl-CoA
dehydrogenase; VLCAD, very long chain
acyl-CoA
dehydrogenase;
CPT1α,
carnitine
palmitoyltransferase
1α;
HMGCS, HMG CoA synthase. Colors as
in Figure 40.

Figure 40.
Foxa2 mRNA levels in
adenovirus-injected ob/ob mice. Primers
were designed to recognize both rat and
mouse isoforms. Values shown represent
the mean ± SEM, n≥3.

Figure 41.
Emut does not activate
mitochondrial β-oxidation in ob/ob livers.
The formation of 14CO2 from 14C-palmitic acid
was measured from liver mitochondrial
extracts from ob/ob mice 10 days after
injection with the indicated adenovirus.
Values shown represent the mean ± SEM. *,
p< 0.05; **, p<0.01; ***, p< 0.001 by unpaired
t-test compared to Ad-GFP; n≥4.

Figure 42. Emut does not activate liver ketone
The
body production in ob/ob mice.
formation of 14C-acid-soluble products from
14C-palmitic acid was measured from liver
mitochondrial extracts from ob/ob mice 10
days after injection with the indicated
adenovirus. Values shown represent the mean
± SEM. *, p< 0.05; **, p<0.01; ***, p< 0.001
by unpaired t-test compared to Ad-GFP; n=4.
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As a physiological readout, we measured hepatic mitochondrial fatty acid
β-oxidation and ketone body production in the livers of hyperinsulinemic ob/ob
mice that were infected with either Ad-GFP, Ad-Foxa2, Ad-T156A, Ad-Emut,
or Ad-TAE. Consistent with the gene expression data, fatty acid oxidation and
ketone body production remained unchanged in the Ad-Foxa2 and Ad-Emut
injected mice, indicating that both are functionally inactive in hyperinsulinemic
conditions. On the contrary, phosphorylation-deficient Ad-T156A and AdTAE groups were immune to inactivation by insulin and showed significant
increases in fatty acid metabolism (Figure 41, Figure 42).

Figure 43. Liver and Plasma lipids in adenovirus-injected ob/ob mice. (A) Lipids were extracted
from 50 mg of liver tissue by the Folch method, weighed and recorded as a percentage of the original
tissue weight. (B) Triglycerides were measured from plasma samples taken after a moderate 6 hour
fast over the course of the experiment. Values shown represent the mean ± SEM. *, p< 0.05; **,
p<0.01; ***, p< 0.001 by unpaired t-test compared to Ad-GFP; n≥4.

As an additional readout of fatty acid metabolism we assayed liver lipids
and plasma triglycerides. Hepatic lipid content (shown as percent wet weight)
revealed a similar trend Figure 43A), with decreases observed only in Ad-
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T156A and Ad-TAE groups. Plasma triglycerides showed an inverse trend
(Figure 43B).
Blood glucose and plasma insulin levels were also measured in these
mice, and both decreased significantly over 10 days in the T156A and TAE
groups mice, whereas no decrease was seen in Ad-Foxa2 or Ad-Emut groups
(Figure 44, Figure 45).

In contrast to previous assumptions, these data

demonstrate that nuclear exclusion is not necessary for insulin-induced
transcriptional inactivation of Foxa2.

Figure 44. Emut is unable to normalize
Blood
blood glucose in ob/ob mice.
glucose was measured from plasma samples
taken after a moderate 6 hour fast over the
course of the experiment. Values shown
represent the mean ± SEM. *, p< 0.05; **,
p<0.01; ***, p< 0.001 by unpaired t-test
compared to Ad-GFP, n=5.

Figure 45. Emut is unable to decrease
plasma insulin levels in ob/ob mice.
Insulin was measured from plasma
samples taken after a moderate 6 hour fast
over the course of the experiment. Values
shown represent the mean ± SEM. *, p<
0.05; **, p<0.01; ***, p< 0.001 by unpaired
t-test compared to Ad-GFP; n=4.
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3.5 Summary
Herein, we demonstrate that Foxa2 contains a functional CRM1dependent (LMB-sensitive) nuclear export site, which is necessary for its
nuclear exclusion in response to insulin stimulation.

Our data clearly

demonstrate that ablation of the nuclear export site, both in vitro and in vivo,
results in constitutively nuclear Foxa2 that is still rendered transcriptionally
inactive upon insulin stimulation.

In addition, we have shown that

phosphorylation at T156 is necessary for both nuclear export and
transcriptional inactivation, since export mutants that are constitutively located
in the nucleus are still phosphorylated by insulin signaling, and additional
T156A mutation restores constitutive Foxa2 activity. Thus, we show here for
the first time that intracellular relocation is a secondary effect and that Aktdependent phosphorylation is a more direct determinant of Foxa2 activity and
its physiological functions in maintaining hepatic lipid metabolism.
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CHAPTER 4: Pulmonary Regulation of Foxa2 by insulin
4.1 Foxa2 expression in the lung
As previously mentioned, Foxa2 is expressed early in development in the
node, notochord and floor plate, while in adult animals it is expressed in
endodermally derived tissues such as the liver, pancreas, lung and gut (19, 31,
66, 67). While the lung is not generally considered an insulin-sensitive organ, it
does play a role in metabolism. In addition to its respiratory functions, the lung
has been demonstrated to act as a filter for certain metabolites, such as
serotonin, and is the main source of angiotensin converting enzyme (ACE)
(68).

Perhaps the most well appreciated metabolic function of the lung,

however, is the production and secretion of surfactant.
Pulmonary surfactant is an amphipathic lipoprotein complex composed
of ~90% lipid and 10% protein (69). Its major function is to maintain low
levels of surface tension at the air-liquid interface in lung alveoli, and thus allow
for more efficient gas exchange, in addition to preventing lung collapse. For
this reason, surfactant production is most critical for the transition to air
breathing at birth, although it has also been linked to breathing disorders later
in life. Both in mice and humans, mutations or deletions in the genes coding
for surfactant protein B and C (SP-B and -C, two of the four major surfactant
proteins), are associated with respiratory failure and interstitial lung diseases,
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which can be lethal without lung transplantation (70, 71). More recently,
additional proteins involved in surfactant production have been linked to
respiratory diseases including proteins involved in lipid transport such as
ABCA3 (ATP-binding cassette A3, a lipid transporter), as well as transcription
factors regulating the expression of important surfanctant genes such as TTF-1
(thyroid transcription factor 1) and Foxa2 (72, 73).
In mice, Foxa2 is expressed in a subset of respiratory epithelial cells in
the lung throughout development. In adult animals its pulmonary expression is
restricted to epithelial cells of the bronchi, bronchioles, alveolar type II cells,
and at lower levels in the trachea.

Notably, its expression overlaps both

temporally and spatially with the expression of key surfactant genes including
SP-B, SP-C, CCSP and TTF-1, which have been shown to be Foxa2 targets
(74-78).

Furthermore, Wan and colleagues demonstrated that conditional

deletion of Foxa2 in the lung impaired lung maturation and surfactant
production, and resulted in respiratory failure and death, further emphasizing
the crucial role of Foxa2 in lung development and surfactant production (79).
Despite the fact that the lung is not generally considered a metabolic
organ, demonstration of such an important role for Foxa2 activation in the
lung caused us to speculate as to whether insulin might also inhibit the
activation of Foxa2 in the lung, and whether this might interfere with
pulmonary function in hyperinsulinemic conditions. Indeed, Type 2 diabetes
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has been suggested to be associated with certain chronic respiratory diseases
such as asthma and COPD (80-82). While most of the genetic abnormalities
discussed so far result in respiratory failure and lethality, chronic lung diseases
are more common and less well understood (83). Additionally, there is known
to be an increased risk of respiratory distress syndrome in newborns of diabetic
mothers (84, 85). These mothers are generally hyperinsulinemic, but insulin
resistant and therefore hyperglycemic.

While insulin does not cross the

placenta, glucose does, and an excess of blood glucose stimulates the fetal
pancreas to produce more insulin, thus rendering the fetus hyperinsulinemic.
Taken toghether, these findings have led us to hypothesize that increased
insulin levels may lead to nuclear exclusion and inactivation of Foxa2 in the
lung, thus inhibiting transcription of important surfactant genes and providing
a link between hyperinsulinemia and respiratory problems in type 2 diabetes.
4.2 Insulin induces nuclear exclusion of Foxa2 in the lung
To address whether insulin induces nuclear exclusion of Foxa2 in the
lung, fasted C57Bl/6 mice were given injections of either PBS or PBS
containing 600ng insulin. Ob/ob (leptin-deficient) mice were used as a model of
hyperinsulinemia and were given no injections. 20 minutes post-injection the
mice were sacrificed and nuclear extracts were made from whole lungs
following a protocol previously established for the liver (10). Livers were
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analyzed as a positive control and, as expected, livers derived from C57Bl/6
mice injected with insulin, as well as hyperinsulinemic ob/ob mice, showed
nuclear exclusion of Foxa2 (Figure 21).

Similarly, the lung showed clear

nuclear exclusion of Foxa2 in response to insulin and in ob/ob mice, even with
25% more protein loaded in insulin and ob/ob lanes (Figure 46).

Figure 46. Nuclear exclusion of Foxa2 in
lungs of insulin-treated and hyperinsulinemic
mice. Western blots of nuclear extracts

prepared from lungs and livers of fasted
C57B6 and ob/ob mice injected with
either PBS or 600 ng of insulin.

Though the predicted molecular weight of Foxa2 is 50 kDa, it generally
runs around 55 kDa by SDS-PAGE. This is approximately the same mass as
mouse IgG heavy chain, and the two polypeptides may comigrate in a gel. To
ensure that the band we observed in the PBS lanes was not due to
contaminating IgG (since a mouse monoclonal antibody was used to detect to
Foxa2) we probed a control blot using only anti-mouse secondary antibody.
After an hour long exposure (compared to a 4 minute exposure in Figure 46)
we observed minimal IgG contamination, and the intensity of the
Figure 47.
No effect of IgG
contamination on shuttling of Foxa2.
Blots from Figure 46 were preincubated
with anti-mouse secondary antibody to
control for background bands.
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contaminating heavy chain species was higher in the ob/ob extracts than the
PBS samples (Figure 47). Thus, detection of Foxa2 in these samples was not
compromised by IgG contamination.
To determine whether this effect was relevant at physiological levels of
insulin, we repeated the experiment in C57Bl/6 mice that were either fasted for
24 hours or allowed to eat normally, and again included ob/ob mice as a
control. Nuclear extracts of lungs from these mice showed that postprandial
insulin levels alone were enough to induce the nuclear exclusion of Foxa2 in
fed mice (Figure 48). Ob/ob mice also showed clear nuclear exclusion of
Foxa2. Ponceau staining or antibody against the generic TAF100 transcription
factor were used as loading controls.

Figure 48. Nuclear exclusion of Foxa2 in
lungs at physiological insulin levels.
Immunoblot analysis of Foxa2 in nuclear
extracts from livers of C57BL/6 and ob/ob
mice, fasted for 24 h or ad libitum fed.
Nuclear extracts were prepared by sucrose
gradient fractionation and each lane
represents livers pooled from 2 mice.

After development of the cellular fractionation protocol discussed in
chapter 2, we repeated these experiments in triplicate in fasted, fed, insulininjected C57Bl/6, and ob/ob mice. As expected, Foxa2 was once again found in
the nucleus of lungs of fasted mice, but was excluded from the nuclear
fractions in fed, insulin-injected and ob/ob mice (Figure 49). Accordingly, we
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were able to see Foxa2 in the cytoplasmic fractions only in lungs from fed,
insulin-injected and ob/ob mice.

Figure 49. Foxa2 relocates to the cytoplasm in lungs of fed and hyperinsulinemic mice. Immunoblots
of nuclear and cytoplasmic fractions from lungs of fasted, fed or insulin-injected C57Bl/6 mice, and
fasted ob/ob mice.

4.3 Surfactant gene expression in adult lung
To determine whether the inhibition of Foxa2 in fed mice has an effect
on surfactant gene expression we prepared RNA from lungs of fasted or ad
libitum fed mice, and analyzed expression levels of candidate Foxa2 target genes
by realtime PCR. While we did observe a slight decrease in SP-A , SP-B and
Aqp3 (aquaporin 3, a water channel protein whose transcription is activated by
Foxa2 in reporter assays (86)), only SP-A was significantly downregulated
(Figure 50).

Figure 50. Surfactant gene expression in lungs of fasted and fed mice. RNA was prepared from lungs
of C57Bl/6 mice that were fasted overnight or ad libitum fed. RNA was reverse transcribed and
relative gene expression was measured by quantitative realtime PCR, normalized to either GAPDH
(left panel) or 36B4 (right panel). Values represent the mean ± SEM; **, p<.01 by two-tailed students
t-test relative to fasted controls, n≥3.
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SP-A has been previously associated with Foxa2 due to its decreased
expression in Foxa2∆/∆ lungs, and there is evidence that insulin leads to
inhibition of SP-A in a PI3-K-dependent manner (79, 87), suggesting that it
could potentially be a direct target. However, this is debatable since reporter
assays failed to show that Foxa2 can directly activate its transcription (79).
Since the expected downregulation of SP-B and CCSP in fed mice was
not observed by realtime PCR we took a more unbiased approach to identify
potential Foxa2 target genes that are regulated by nutritional status. mRNA
was prepared from total lung RNA of fasted and fed C57Bl/6 mice, pooled,
and compared by Affymetrix microarray hybridization. Table 2 shows the
most downregulated and upregulated genes in the fed compared to the fasted
state. Since Foxa2 generally acts as a transcriptional activator we consider the
downregulated genes most likely to be direct targets of Foxa2.
Once again we saw no significant changes in surfactant genes, and no
obvious target genes linking nutritional status to pulmonary function. It should
be noted, however, that this experiment only compared lungs of adult, healthy,
wildtype mice in fed and fasted states, and not more extreme hyperinsulinemic
conditions. We therefore decided to investigate Foxa2 in a more demanding
context.
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Gene
chloride channel calcium activated 3
chitinase 3-like 4
eosinophil-associated, ribonuclease A family, member 11
resistin like alpha
cDNA sequence BC055107
serum amyloid A 3
solute carrier family 26, member 4
chloride channel calcium activated 1 ; chloride channel calcium activated 2
cDNA sequence BC055107
pyruvate dehydrogenase kinase, isoenzyme 4
anterior gradient 2 (Xenopus laevis)
angiopoietin-like 4
PREDICTED: zinc finger and BTB domain containing 16 mRNA

Fold downregulation
46.3
23.6
6.9
6.6
4.7
4.4
4.3
4.2
3.9
3.9
3.5
3.5
3.4
RIKEN cDNA 2210019G11 gene
3.4
Hexaribonucleotide binding protein 3 (Hrnbp3)
3.4
lysyl oxidase
3.3
Transcribed locus
3.3
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N3.3
l l
i l
f
lik 2
DNA-damage-inducible transcript 4
3.2
Gene
Fold upregulation
cathelicidin antimicrobial peptide
8.172
neutrophilic granule protein
3.838
major urinary protein 1 ; major urinary protein 2
3.704
lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase)
2.866
mannosidase 2, alpha B2
2.701
cytochrome P450, family 1, subfamily a, polypeptide 1
2.548
WNT1 inducible signaling pathway protein 1
2.479
Lecithin-retinol acyltransferase (Lrat), mRNA
2.455
chemokine (C-X-C motif) ligand 7
2.417
regulator of G-protein signaling 18
2.319
transmembrane protein 46
2.255
PREDICTED: Mus musculus RIKEN cDNA 9630020C08 gene
2.238
RIKEN cDNA 8430417A20 gene
2.221
DNA segment, human D4S114
2.217
checkpoint kinase 1 homolog (S. pombe)
2.201
limb-bud and heart
2.187
solute carrier family 7 (cationic amino acid transporter, y+ system),
2.174
b 10
tumor necrosis factor (ligand) superfamily, member 10
2.166
Insulin-like growth factor 1, mRNA (cDNA clone MGC:18617
2.165
Table 2. Highest down and upregulated genes in fed lung. Biotin-labelled cRNA samples from 5
fasted and 5 fed mice were pooled and hybridized to an Affymetrix GeneChip Mouse Genome 2.0
array. Shown are the 19 highest down and upregulated genes in fed compared to fasted mice.
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4.4 Nuclear exclusion of Foxa2 in Fetal lungs
Since previous studies have demonstrated a critical role for Foxa2 in
lung development and the transition to air breathing, we first investigated
whether insulin also regulates the nuclear localization of Foxa2 in the fetus.
Timed pregnancies were set up in wildtype C57Bl/6 mice and allowed to
progress to embryonic day 19 (E19), at which point lung development is nearly
complete (88). Pregnant females were either fasted, or allowed to feed freely
for 16 hours prior to sacrifice, and cellular localization of Foxa2 was assessed in
maternal and fetal liver and lung tissue. In accordance with previous data,
Foxa2 is nuclear in maternal tissue from fasted mice, as well as in the lung and
liver of fetuses from fasted mothers (Figure 51). This is in startk contrast to ad
libitum fed pregnant females, where Foxa2 is excluded from the nucleus in
maternal and fetal lung and liver (Figure 52). Here we demonstrate, for the
first time, that Foxa2 shuttling also occurs in the fetus, and that its cellular
localization is linked to the nutritional state of the mother.

Figure 51. Foxa2 is nuclear in liver and lung of fasted fetuses. Nuclear and Cytoplasmic fractions
from wildtype fasted maternal (M2) or E19 fetal (E1, E2) liver (Lv) and lung (Lu) were immunoblotted
for Foxa2. TP1 and TP2 indicate individual timed pregnancies.
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Figure 52. Foxa2 is cytoplasmic in fetal liver and lung of fed mice. Nuclear and Cytoplasmic
fractions from wildtype ad libitum fed maternal (M) or E19 fetal (E1,4,6) liver and lung were
immunoblotted for Foxa2.

Since insulin does not cross the placenta, we could not directly test the
effect of insulin on the localization of Foxa2 in fetal tissues by injection.
Instead, we took advantage of two mouse models of diabetes that are
hyperglycemic and thus induce hyperinsulinemia in the fetus.
SREBP-1cAp2 (SREBP) transgenic mice, express nuclear Sterol
regulatory element-binding protein (SREBP) 1c only in adipose tissue, but
subsequently have a pronounced type 2 diabetic phenotype with marked
hyperinsulinemia, insulin resistance and hyperglycemia (89).

Previous data

from the lab has shown that Foxa2 is constitutively cytoplasmic and inactivate
in livers of these mice (10). We now show that Foxa2 is also constitutively
cytoplasmic in lungs of these mice. Additionally, maternal hyperglycemia in
these animals is able to signal a constant “fed” state even in these fasted mice,
and thus triggers insulin secretion, as evidenced by nuclear exclusion of Foxa2
in fetal lungs of these mice (Figure 53).
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Figure 53. Nuclear exclusion of Foxa2 in fetal lungs of SREBP mice. Immunoblots of nuclear and
cytoplasmic extracts from lungs of fasted SREBP mice. M, maternal lung; E1-4, E19 fetal lung; C,
fasted lung whole cell lysate as a control; TBP, TATA binding protein.

The second mouse model we used to demonstrate the effect of aberrant
insulin signaling on Foxa2 localization in fetal tissue is streptozotocin-induced
diabetic mice, a model for Type I diabetes. Streptozotocin (stz) targets and kills
pancreatic

beta

cells,

inducing

hypoinsulinemia

and,

consequently,

hyperglycemia. Thus, these mice provide an elegant approach to studying the
effects of maternal hyperglycemia on Foxa2 localization in wildtype fetuses.
Fasted stz-treated mothers, in accordance with their hypoinsulinemic state,
show Foxa2 localization in the nucleus in liver and lung (Figure 54).

Figure 54. Differential Foxa2 localization in maternal and fetal livers and lungs of Stz mice. Pregnant
C57Bl/6l mice were given injections of 3x75 mg/kg stz on E14-16. Mice were fasted on E18, sacced
on E19 and nuclear and Cytoplasmic fractions maternal (M) or E19 fetal (E1, E5) liver (Lv) and lung
(Lu) were subject to immunoblot analysis.
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Conversely, fetuses of these hyperglycemic mothers retain beta cell
function and secrete insulin, which results in cytoplasmic relocalization of
Foxa2 only in fetal tissues (Figure 54).
To study the effect of hyperinsulinemia on gene regulation in fetal lungs
we compared mRNA expression profiles from wildtype, fasted fetuses and stztreated fetuses. Agilent microarray analysis revealed 37 genes which were
found to be significantly downregulated and 103 genes significantly upregulated
more than 2 fold in stz-lungs compared to fasted wildtype controls (Table 3).
While we have not yet verified any of these genes in the lung,
preliminary cDNA analysis of fetal livers from stz and wildtype fasted fetuses
by RTPCR shows a significant decrease in known Foxaa2 target genes
including MCAD, VLCAD and CPT1 (Figure 55).

This analysis was

preliminary due to the limited n number, however it suggests that the model is
sound. It is also reassuring to note that several of the top downregulated genes
in the agilent list have already been linked to Foxa2 in the literature. Reg3g, has
been shown to be a Foxa2 target gene in vitro, and is the highest downregulated
in our list (90). Scgb3a1, the second most downregulated gene in stz-lungs is a
homolog of CCSP, a secrotoglobulin also regulated by Foxa2 (91).
Additionally, muc5b (mucin 5b) is a related to muc2, the main component of
intestinal mucous which is regulated by Foxa1 and 2 in intestinal eplithelial cells
(92).
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Gene
Reg3g
Scgb3a1
Muc5b
Agr2
Mfi2
1110017I16Rik
Matn3
Col9a1
C1qtnf3
Col9a3
Lect1
3110079O15Rik
Agc1
Chac1
Adh7
Cart
A930038C07Rik
BC006965
9030611K07Rik
Gene
Pln
Prap1
Ckmt2
Nppa
Ftcd
Dhrs7c
C78409
Xist
Apoa5
Nefh
Pah
9630020C08Rik
Cyp3a16
Slco1b2
Fthl17
Ankrd1
Hfe2
Angptl3
Bhmt

Fold downregulation
78.98
31.79
31.34
22.71
16.90
16.67
14.50
11.89
10.69
9.74
8.63
8.34
7.96
7.22
5.65
5.22
4.71
4.36
4.05
Fold upregulation
169.7
71.3
65.3
25.5
21.5
15.5
14.8
14.4
10.1
8.1
7.6
5.9
5.8
5.7
5.7
5.4
5.4
5.1
5.0

Gene
A_52_P444116
Chst5
Krt5
Klk10
Vip
A_52_P686218
A_52_P257026
B230303O12Rik
2310068J10Rik
AK163997
Gzmb
D130076A03Rik
Mfsd2
Abcg5
Nr1i3
AK154840
E430002D04Rik
Nptxr
Gene
Akr1b7
Serpina1e
Agxt
Cyp3a41
Kng1
F13b
Cps1
Fabp1
Abcb11
Pck1
Slc10a1
Apoa1
Sult1d1
Bhmt2
Dmgdh
Hsd17b13
Clec4f
Serpina1b
Spp2

Fold downregulation
3.77
3.55
3.31
3.26
3.23
3.02
2.95
2.92
2.91
2.87
2.85
2.69
2.64
2.51
2.41
2.37
2.03
2.01
Fold upregulation
4.8
4.8
4.8
4.7
4.7
4.6
4.5
4.4
4.3
4.1
4.1
4.0
4.0
4.0
4.0
3.9
3.9
3.7
3.6

Table 3. Genes altered in fetal lungs of stz-mothers. Highest up and downregulated genes in stz
compared to fasted fetal lungs were identified using 4x44 Agilent whole mouse genome microarray
service (miltenyi) and further analyzed using GenespringGX software.
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Figure 55. Foxa2 β-oxidation genes are inhibited in fetal livers of stz mothers. Realtime PCR analysis
of Foxa2 target genes in cDNA made from livers of fetuses from C57Bl/6 fasted or stz-induced
diabetic mothers. Values are means, normalized to GAPDH ± SEM shown relative to fasted fetal liver
samples, which were sset to 1. *, p≤.05; **, p ≤ 0.01. MCAD, medium chain acyl-CoA
dehydrogenase; VLCAD, very long chain acyl-CoA dehydrogenase; CPT1, carnitine
palmitoyltransferase 1α. n≥2.

4.5 Summary
Though the lung is not considered a major metabolic organ, we have
found that Foxa2 localization is regulated by insulin in the lung as it is in the
liver. In lungs of adult mice Foxa2 is excluded from the nucleus following
insulin injection, as well as by physiological levels of insulin experienced in the
fed state.

Furthermore it is constitutively cytoplasmic in lungs of

hyperinsulinemic ob/ob mice. The increased incidence of lung disorders in
babies of diabetic mothers, which are similar to that observed in Foxa2 lung
conditional knockout mice, led us to search for a correlation between
hyperinsulinemia, Foxa2 inactivation, and the production of surfactant
proteins. In lungs of adult mice, RTPCR and microarray analysis failed to
provide clear evidence that Foxa2 inactivation in the fed state links nutritional
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status to pulmonary function. However, we did observe a slight but significant
downregulation in SP-A gene expression by RTPCR.
While microarray analysis of gene expression in fetal lungs from stzinduced diabetic mothers was also unable to directly correlate Foxa2 regulation
to surfactant production, we do clearly observe insulin-dependent inactivation
of Foxa2 both in fetal liver and lung. In normal mice and in mouse models of
diabetes, we find that Foxa2 in the embryonic lung (and liver) is excluded from
the nucleus in conditions of high blood glucose. This sensitivity of Foxa2 to
maternal glycemic state leaves open the possibility that there is a link between
diabetic mothers and fetal lung development and function.
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CHAPTER 5: Shuttling of Foxa2 in the Hypothalamus
5.1 Hypothalamic expression of Foxa2
In addition to aforementioned regions, Foxa2 is also expressed in the
brain, including certain regions of the hypothalamus (19). Using Xgal knock-in
mice (Foxa2+/lacZ) in which one allele of Foxa2 is replaced by the LacZ gene, we
have further mapped the expression of Foxa2 in the central nervous system.
X-gal staining was observed in the lateral hypothalamic area, paraventricular
hypothalamic area, zona incerta, and substantia nigra (Silva J, unpublished
data). However, the function of Foxa2 in these cells is not well understood.
Given the newly emerging view of Foxa2 as an important sensor and regulator
of metabolic genes, we found its expression in the lateral hypothalamus
(considered to be the feeding center of the brain) to be of particular interest
(93).
While the hypothalamic role of Foxa2 has not yet been appreciated, the
anorectic effects of insulin and its subsequent activation of the
phospatidylinositol 3 kinase (PI3K)/IRS/Akt signaling pathway in the
hypothalamus are well documented (94-96). In the arcuate nucleus, these
effects have been shown to be mediated in part by suppression of orexigenic
neuropeptides such as neuoropeptide Y (Npy) and Agouti-related protein
(Agrp),

while

activating

the

expression
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of

anorexigenic

Pomc

(proopiomelanocortin) at the same time (97). Inactivation of Foxo1 by insulin
and leptin has been shown to play a key role in these regulatory events (98).
Neurons in the lateral hypothalamus also respond to feeding and fasting,
and control food intake as well as spontaneous physical activity due in large
part to the effects of orexin and MCH (99, 100). However, the mechanism and
metabolic stimuli controlling their regulation in response to feeding and fasting
is unknown. Dual immunofluorescence labeling with Foxa2 and MCH or
orexin reveals that all MCH and orexin positive neurons also express Foxa2
(Silva J, unpublished data). Thus we hypothesized that insulin-induced nuclear
exclusion of Foxa2 could mediate feeding-induced inhibition of MCH and
orexin, and thus appetite and food seeking behavior.
5.2 Insulin induces nuclear exclusion and inactivation of Foxa2 in the
hypothalamus
To begin to address the role of Foxa2 in the hypothalamus, we first
sought to determine whether it is inactivated by insulin signaling in this portion
of the brain. Hypothalami were dissected from fasted or ad libitum fed wild
type mice, subjected to cellular fractionation and assayed for nuclear exclusion.
As shown in Figure 56, Foxa2 is nuclear in hypothalami from fasted mice, but
cytoplasmic in fed mice.
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To demonstrate that this regulation is
due specifically to increased postprandial
insulin levels and not blood glucose
concentrations, we isolated hypothalami
from fasted wildtype mice and incubated
Figure 56.
Insulin induces nuclear
exclusion
of
hypothalamic
Foxa2.
Immunoblot analysis of nuclear and
cytoplasmic extracts prepared from
pooled hypothalami from 3 mice each that
were either fasted overnight or ad libitum
fed. TBP, TATA binding protein.

them ex vivo in basal media with low glucose,
high glucose, or low glucose plus insulin.
Neither low nor high glucose concentrations

are sufficient to induce nuclear export of Foxa2, however Foxa2 did shuttle
when insulin was added to the low glucose media (Figure 57)

Figure 57. Hypothalamic nuclear exclusion of Foxa2 is insulin and not glucose-dependent.
Immunoblot analysis of nuclear and cytoplasmic extracts prepared from hypothalami incubated ex
vivo in DMEM with either low (5 mM) or high (16 mM) glucose, in the absence or presence of 10
ng/mL of human recombinant insulin.

In order to study the effects of constitutive inactivation of Foxa2 in the
hypothalamus, we analyzed high fat diet-induced obese mice, which provide a
hyperinsulinemic model of type 2 diabetes. As expected, high fat diet-induced
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obesity and the corresponding increases in plasma insulin result in constitutive
nuclear exclusion of Foxa2 in the hypothalami of these mice. While Foxa2 is
completely nuclear in fasted chow fed mice, cytoplasmic levels of Foxa2 in
hypothalmi from high fat diet-fed mice are similar to those of ad libitum fed
controls (Figure 58).

Figure 58. Foxa2 is constitutively cytoplasmic in hypothalami from high fat diet-fed mice.
Immunoblot analysis of nuclear and cytoplasmic extracts prepared from hypothalami of fasted, fed or
fasted high fat diet-fed mice. Each lane represents hypothalami pooled from 2 mice. γ-Tubulin was
used as a general loading control, and LSD1 (Lysine-specific demythlase 1) and GAPDH served as
nuclear and cytoplasmic extraction controls, respectively.

Correspondingly, expression of both MCH and orexin was decreased by
~60% in hypothalami of fed and high fat diet-fed mice, compared to fasted
controls (Figure 59). Further work in the lab has shown that MCH and orexin
are

direct

targets

of

Foxa2

in

immunoprecipitation experiments.
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transactivation

and

chromatin

Figure 59. Real-time RT-PCR analysis of MCH and orexin in fasted, chow fed and fasted, high fat
diet-fed (HF) mice. Results are expressed as amount of cDNA normalized to GSPDH cDNA. The
values represent the mean ± sem (n=5 in all groups; *, P<0.05; **, P<0.01).

5.3 Constitutive activation of Foxa2 in the hypothalamus
In order to show that Foxa2 activation is sufficient to induce metabolic
changes associated with MCH and orexin we constitutively activated Foxa2 in
hypothalamic nuclei by 3 different means. First, conditional mutant mice with
a constitutively active Foxa2-T156A allele were generated by introducing loxP
sites upstream and downstream of exon 3, which encodes most of the open
reading frame of Foxa2 as well as the 3’ untranslated region. An exon 3
duplication, harboring the T156A mutation, was introduced downstream of the
floxed wildtype exon 3 and neuron specific recombination was obtained by
breeding to nestin-Cre mice.

These mice show significantly increased

expression of MCH and orexin, as well as CPT1, MCAD and VLCAD, Foxa2
target genes involved in mitochondrial β-oxidation (Figure 60).
Accordingly, these mice show a significant enhancement of metabolic
function. Serum glucose levels, plasma insulin levels and serum free fatty acid
concentrations are all decreased in the fed state in Nes-Cre/Foxa2T156Afl/fl
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mice compared to control littermates (Figure 61). Glucose clearance from the
circulation following an insulin tolerance test is modestly increased in NesCre/Foxa2T156Afl/fl mice, indicating increased insulin sensitivity (Figure 61).

Figure 60. Real-time RT-PCR analysis of gene expression in mice with neuron-specific activation of
Foxa2. cDNA was prepared from hypothalami of fed Nescre/+, Foxa2T156Afl/fl mice, fed
Foxa2T156Afl/fl mice and fed Nescre/+ mice. Relative expression of MCH, Orexin, CPT1, Mcad, and
Vlcad was normalized to β-actin or GAPDH housekeeping genes. The results are expressed as foldinduction over fed Foxa2T156Afl/fl mice and represent the mean ± SEM.

Figure 61. Altered serum parameters in Nes-Cre/Foxa2T156Afl/fl mice. Blood glucose, percentage of
starting plasma glucose concentration during an insulin tolerance test, plasma insulin and plasma
Free fatty acids were measured in in Nescre/+, Foxa2T156Afl/fl mice, Nescre/+ mice, and
Foxa2T156Afl/fl mice.
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Measurements of metabolic rates reveal that Nes-Cre/Foxa2T156A fl/fl
mice have increased O2 consumption and CO2 production, and exhibit
dramatic increases in spontaneous physical activity over 24 hours compared to
Nes-Cre/+ and Foxa2T156A fl/fl control mice (Figure 62).

Food

consumption and drinking volume are also increased in Nes-Cre/Foxa2T156A
fl/fl animals (Data not shown).

Figure 62. Altered metabolic parameters in Nes-Cre/Foxa2T156A fl/fl mice. Spontaneous physical
activity during a light phase 12 hr interval, oxygen consumption and CO2 production were determined
simultaneously during a 24-h period in individual mice using an oxymax metabolic chamber system.

To ensure that these effects were not due to activation of Foxa2 in
neurons outside of the hypothalamus we used two alternate methods to express
constitutively active Foxa2 specifically in the hypothalamus:

injection of

constitutive Foxa2-T156A adenovirus into the hypothalamus of wildtype mice,
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and direct injection of adenovirus CRE into hypothalami of Foxa2T156A fl/fl
mice.

Cellular fractionation confirmed the expression and constitutively

nuclear localization of Foxa2-T156A in fed mice injected with either Ad-T156A
or Ad-Cre, while endogenous Foxa2 is cytoplasmic (Figure 63, Figure 64).
Both of these methods achieved similar results to the Nes-Cre/Foxa2T156A
fl/fl experiments, demonstrating that the metabolic phenotypes are due to
constitutive activation of Foxa2 in the hypothalamus.

Figure 63. Hypothalamic expression and localization of Foxa2 after AdT156A injection. C57Bl/6
mice were given hypothalamic injections of adenovirus expressing GFP or Foxa2-T156A.
Immunoblots of cellular fractionation experiments are shown.

Figure 64. Hypothalamic expression and localization of Foxa2 after AdCre injection in NesCre/Foxa2T156A fl/fl mice. Nes-Cre/Foxa2T156A fl/fl mice given hypothalamic injections of either
GFP or Cre adenovirus. Immunoblot analysis of nuclear and cytoplasmic fractions are shown.
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5.4 Summary
These studies reveal a molecular mechanism by which insulin controls
the feeding/fasting response of the lateral hypothalamus. In fasting conditions,
Foxa2 acts as a direct transcriptional activator of MCH and orexin genes,
thereby stimulating classical fasting responses such as feeding, behavioral
arousal and spontaneous physical activity. In the fed state, Foxa2 is
phosphorylated by insulin/PI3K/Akt signaling, which leads to Foxa2
inactivation and nuclear exclusion. Interestingly, MCH and orexin expression
is regulated by the same metabolic stimuli and molecular signaling pathway,
thereby integrating metabolic and adaptive behavioral responses. Similar to
what we have shown for the liver and lung, Foxa2 is permanently inactive in
MCH and orexin neurons in hyperinsulinemic states such as type 2 diabetes,
resulting in reduced MCH and orexin expression. Conditional constitutive
activation of Foxa2 in the hypothalami of these mice leads to increased physical
and metabolic activity, improved glucose homeostasis, and increased insulin
sensitivity.
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DISCUSSION
Affect of genetic variation on Foxa2 regulation and associated metabolic
activity
While data support a role for Foxa2 as a metabolic transcription factor,
there is conflicting evidence regarding its inactivation, particularly its nuclear
exclusion by insulin.

Our studies confirm that Foxa2 can be inactivated

through insulin-induced nuclear exclusion in all mouse strains tested.
However, marked differences exist in the modulation of metabolic pathways by
insulin signaling with respect to background genetic strain differences. The
inherent metabolic differences in the strains studied are exemplified by their
responses to high fat diets. C57Bl/6 mice are generally more obese, glucose
intolerant, and hyperinsulinemic on high fat diets and exhibit higher levels of
liver triglycerides, increased hepatic steatosis, and insulin sensitivity than their
129 counterparts (101) (102). These findings are in line with our observations,
which demonstrate that in addition or due to having lower insulin levels, Sv129
mice have higher rates of β-oxidation and increased oxygen consumption in
comparison to C57/B6 mice. Accordingly, only in C57Bl/6 and dba mice were
the postprandial levels of insulin high enough to effect nuclear exclusion of
Foxa2 under physiological circumstances.
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These data provide a plausible

explanation for the observed discrepancies in nuclear exclusion of Foxa2
reported by Zhang et al (11).
We also demonstrate that primary hepatocytes from hyperinsulinemic
insulin resistant mice (ob/ob, db/db and HF-diet induced obese mice) are
capable of shuttling Foxa2 back into and out of the nucleus in culture, while
Foxa2 is always cytoplasmic in livers of these mice in vivo.

These data

demonstrate that hepatocytes from these mice are not defective, but accurately
reflect the insulin concentrations to which they are exposed.
Not only do our data demonstrate the importance of genetic background
on metabolism and Foxa2 regulation, but we also find the inverse to be true:
the activation state of Foxa2 is sufficient to account for some of these observed
metabolic alterations. While constitutive activation of Foxa2 in Sv129 mice has
little effect (Foxa2 is already active), constitutive activation in C57Bl/6 mice
normalizes β-oxidation between fasting and feeding states by increasing βoxidation in the fed state, corresponding with Foxa2-dependent activation of
target genes such as Mcad, Vlcad and CPT1.
The increased insulin levels in “obesity-prone” C57Bl/6 inbred mice (in
the fed state) result in the translocation of insulin-dependent hepatic factors
Foxo1 and Foxa2 from the nucleus, which leads to the inhibition of
downstream target genes involved in glucose and lipid metabolism. This could
also serve to set up a negative feedback loop whereby genetic factors in certain
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strains lead to decreased Foxa2 activity (or to increased insulin and thereby
decreased Foxa2 activity) , which in turn leads to decreased metabolism and
enhanced metabolic differences between strains. In such a case, with the
addition of a high fat diet or additional environmental stresses, this negative
feedback could be even further exacerbated in the “obesity-prone” mice,
resulting in this exaggerated phenotype.
The development of diabetes and the associated metabolic syndrome in
humans is also dramatically affected by background genes. In mice, this was
first reported for the ob/ob and db/db traits (53) and has been shown
subsequently in mice with genetically induced lipodystrophy (103), and dietinduced obesity (104). Furthermore, a recent study showed that in the insulin
receptor/IRS-1 double-heterozygous knockout, the background genes of
C57/B6 mice caused severe hyperinsulinemia and diabetes, whereas
background genes of the Sv129 strain protected against diabetes (105). This
"thrifty" phenotype displayed by the C57/B6 mice as shown by weight gain,
hyperinsulinemia, and increased hepatic lipid content is similar to that observed
in various human populations that exhibit an increased susceptibility to obesity
and diabetes, given an average caloric intake (106, 107). Even though the
causes of increased release of insulin are unclear, it may be possible to
counteract some of the pathophysiological conditions that are a direct result of
the metabolic syndrome. Thus, it is of the utmost interest to elucidate ways to
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modulate Foxa2 activity through dephosphorylation and nuclear reactivation,
with the goal of influencing hepatic lipid metabolism and thereby alleviating
symptoms such as hepatic steatosis and insulin resistance.

Inhibition of Foxa2 occurs independently of nuclear exclusion
Previous data from our lab provide evidence for a strong correlation
between insulin signaling, T156 phosphorylation, nuclear exclusion and
inactivation of Foxa2 (10, 36).

While nuclear exclusion certainly leads to

inhibition of transcriptional activity, there was previously no means to
differentiate between these correlative observations. The novel identification of
a functional NES in Foxa2 has now allowed us to uncouple these events.
Interestingly, alignment of the Foxa2 NES shows that it is wellconserved throughout vertebrate homologues of Foxa2.

Minor variations

within the sequence occur from Xenopus to human (methionines instead of
leucines at amino acids 110 and 113), but these changes conserve the overall
character of the export sequence and are not likely to hinder nuclear export
capability. Indeed, it has been shown that hydrophobic residues other than
leucine (including isoleucine, valine, methionine, and phenylalanine) may
constitute a functional CRM1 NES (62, 108). By contrast, this sequence
conservation does not extend to Fork head, the Drosophila homolog of Foxa2.
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Consequently, Drosophila Fork head may not be capable of shuttling in response
to insulin stimulation, suggesting that the nuclear export capability may have
arisen later in evolution. Notably, the T156 phosphorylation site (T207 in
Drosophila) is conserved (36). It will therefore be interesting to see whether the
same mechanism of insulin-induced phosphorylation exists in flies, and
whether this also results in Fork head inactivation.
Mechanisms to this effect have also been reported for the Foxo family
of transcription factors. Phosphorylation of three critical residues in Foxo1 has
been shown to contribute to nuclear export and subsequent loss of
transcriptional activity in response to insulin/IGF signaling (46, 47, 58). In vitro
data suggest that Serine 256 acts as a “gatekeeper” to subsequent regulatory
events, with phosphorylation at this residue resulting in transcriptional
inhibition of nuclear Foxo1 (50, 109). However, additional posttranscriptional
modifications have also been shown to contribute to the regulation of FoxO
family members, including acetylation, ubiquitination and methylation
(reviewed in (110, 111). The relative contribution and exact mechanisms of
these modifications are still being worked out.
Our data support a model whereby phosphorylation of Foxa2 acts as the
dominant signal for transcriptional inactivation; however we cannot exclude the
possibility that additional post-translational modifications exist.

Since we

generally observe that Foxa2 runs about 9 kDa above its predicted molecular
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weight, we asked whether it might be sumoylated or ubiquitinated. Running
the rat Foxa2 amino acid sequence through a sumoylation site predicting
program identified several sites with high probability, and several with low
probability (Figure 65). Intriguingly, one of the high probability sites is very
close to the Akt phosphorylation site.

Figure 65. Sumoylation site prediction. The amino acid sequence for rat Foxa2 was put into
SumoPlot, a sumoylation prediction program. The following high and low probability sites were
predicted. The Foxa2 Akt phosphorylation site is shown in green, for reference.

To test whether Foxa2 is sumoylated we used whole cell lysates from
insulin-treated primary hepatocytes infected with the four Foxa2 variant
viruses.

Surprisingly, we observe a very strong sumoylation signal in

immunoprecipitates, and even in whole cell lysates of all insulin-stimulated
primary hepatocytes, except GFP controls (Figure 66). There did not seem to
be any difference in sumoylation state between the viruses however, and more
data will need to be acquired to determine the function of Foxa2 sumoylation,
and whether it is regulated by insulin.

81

Figure 66. Foxa2 is sumoylated. Primary hepatocytes were infected with the indicated adenovirus,
serum starved overnight and stimulated with 100nM insulin for 15 min. Whole cell lysates were then
saved as input, or immunoprecipitated (IP) with an anti-HA antibody. Immunoblots of input and IPs
were probed with an antibody against SUMO1.

In an attempt to determine whether the phosphorylation site is
sufficient to induce inactivation of Foxa2 we generated Foxa2-T156E or T156D phosphomimetic variants. These both appear to result in constitutively
nuclear Foxa2 when stably expressed in HepG2 cells, although further studies
are needed to sufficiently assay its activation state (data not shown). Thus,
whether this single phosphorylation event is sufficient for inactivation of Foxa2
remains to be determined.
One

plausible

hypothesis

for

the

regulation

of

Foxa2

by

phosphorylation, is that T156 phosphorylation, which occurs N-terminal of the
DNA binding domain, directly decreases the DNA binding affinity of Foxa2.
While EMSA data suggest that this is not the case, it was not possible to
monitor the phosphorylation state of Foxa2 in these assays (36). Alternatively,
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or additionally, phosphorylation (or other modifications) could affect
coactivator or histone binding.
Our data thus provide a novel perspective on the regulation of Foxa2 by
insulin, which can potentially be applied to the hormonal regulation of other
transcription factors.

Additionally, the discovery of an essential NES

controlling insulin-induced nuclear export of Foxa2 lays a strong foundation
for the identification of additional signaling pathways and/or post-translational
modifications involved in the regulation of Foxa2 activity.
The constitutive inactivation of Foxa2 by insulin, in addition to the
beneficial effects of constitutively active Foxa2 in mouse models of obesity
make understanding the molecular mechanisms of its regulation of great
scientific, and potentially therapeutic interest. Taken together, our data show
that Foxa2 is subject to active nuclear export in response to insulin signaling,
that this export is not prerequisite for transcriptional inactivation and that
Foxa2 phosphorylation is the most direct readout of Foxa2 activity.

Pulmonary and embryonic regulation of Foxa2 by insulin
We clearly observe insulin-induced nuclear exclusion of Foxa2 in lung
cells, just as has been previously described for hepatocytes. Expression of
Foxa2 is enriched in lung, as it is in liver, so to some degree it is not surprising
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that it behaves similarly in both tissues. Curiously, though, there is no well
established metabolic reason for gene expression in lung tissue to be regulated
by the routine insulin fluctuations that accompany fasted and fed states.
We hypothesize that an indirect connection between insulin and
metabolism may be found in the production of lung surfactant proteins. Lung
surfactant maximizes the surface area of the lung available for gas exchange,
and therefore expression of surfactant genes may increase the efficiency of
respiration. Efficient respiration, in turn, may permit more efficient use of
energy during periods of activity, and studies have shown that caloric
restriction stimulates locomotion. Indeed, in chapter 5 we report the novel
regulation of Foxa2 by insulin in the hypothalamus, where nuclear Foxa2
(induced by fasting), increases locomotion and food-seeking behavior. In this
way, insulin-dependent regulation of Foxa2 in the lung may correlate with the
overall metabolic state of the organism. This model would also implicate
Foxa2 in one of the developmental disorders associated with type 2 diabetes:
impaired lung function in infants of mothers with uncontrolled gestational
diabetes (84, 85). These mothers are generally hyperinsulinemic, but insulin
resistant and therefore hyperglycemic.

While insulin does not cross the

placenta, glucose does, and an excess of blood glucose stimulates the fetal
pancreas to produce more insulin, thus rendering the fetus hyperinsulinemic.
We hypothesize that this results in the cytoplasmic localization and inactivation
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of Foxa2 in the lungs of fetuses developing in insulin resistant mothers, leading
to reduced surfactant production just prior to their transition to air breathing at
birth. There is also some evidence for an associated risk of respiratory diseases
like asthma and chronic obstructive pulmonary disease in adults with obesity
and type II diabetes (80-82).
The most obvious way for Foxa2 to regulate surfactant production is
through transcriptional control of surfactant genes. Surfactant protein B (SPB) and clara cell secretory protein (CCSP) are both reported Foxa2 target genes
in the lung (76, 112), however our initial realtime PCR analysis for fasted and
fed adult lung show very minor, if any, changes in these genes. Interestingly, a
different surfactant protein, SP-A, was significantly decreased. Furthermore,
several genes from our microarray analysis on embryonic lung look promising
in terms of being potential Foxa2 targets that are also implicated in lung
function: Reg3g, Scgb3a1, and muc5b. While these genes do not encode
surfactant proteins per se, they are all implicated in host defense, suggesting a
possible alternative or additive function for insulin sensitivity in the lung.
Our observations do not preclude the possibility of surfactant regulation
by Foxa2 in a more indirect manner or on a longer timescale. Indeed, the fact
that Foxa2 is expressed in lung and is regulated by insulin strongly suggests that
it mediates some metabolic regulation of this organ. Further study is required
to more fully investigate the possibility of insulin-dependent regulation in lung
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tissue, and to understand the molecular mechanisms responsible for diabetesassociated lung disorders.
Finally, our studies demonstrate that Foxa2 target genes in the liver can
be disregulated by insulin signaling during development, as early as E19. The
long term effects of this early disregulation are not known, however it is
possible that it starts the negative feedback loop discussed earlier, and so sets
the stage for insulin resistance or obesity later in life. If so, this would be
relevant to human forms of the disease which can be “inherited” but are not
always directly linked to genetics.
Regulation of Foxa2 in the Hypothalamus
A well established connection has been noted between the neurons of
the lateral hypothalamus and feeding behavior or arousal (113-116).

For

instance, trauma to the LHA may result in decreased arousal, failure to meet
metabolic challenges by modifications in behavior, and ultimately death by
starvation (117, 118). Our studies elucidate a molecular mechanism through
which metabolic state may influence behavioral responses: insuilin-dependent
signaling in the lateral hypothalamus inhibits Foxa2-dependent expression of
MCH and orexin neuropeptides.
As observed in the liver, Foxa2 in MCH and orexin neurons is nuclear
and active in fasted C57Bl/6 mice, but inactive in fed C57Bl/6 mice and fasted,
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hyperinsulinemic obese mice. We have identified MCH and orexin as novel
targets of Foxa2, and show that their expression is reduced when Foxa2 is
inactivated through insulin signaling. MCH and orexin are known to regulate
food intake and movement, respectively (114, 116, 119, 120). MCH increases
food consumption, and gene deletion causes hypophagia.

Interestingly,

increased expression of MCH on its own results in obesity in susceptible mice;
however increased expression of MCH in Nescre/+,Foxa2T156Afl/fl mice did
not have this effect. This can be attributed to the coregulation of orexin, which
mediates wakefulness and results in increased activity. Orexin gene deletion is
associated with narcolepsy and obesity.

As MCH and orexin signaling are

associated with activity and feeding behavior, their downregulation in this
hyperinsulemic model may constitute a system of negative feedback, which
exacerbates the phenotype.

Indeed, decreased activity is a common

phenomenon overweight individuals, in humans and in mice, and is now
recognized as a major factor contributing to the continuing rise in obesity.
Interestingly, introduction of constitutively active Foxa2-T156A in these
mice leads to improved metabolic properties, including ameliorated glucose
homeostasis, decreased fat and lean body mass, and increased physical activity.
These observations suggest that Foxa2 activation in the hypothalamus may be a
novel therapeutic approach to overcome the metabolic pathologies in diabetic
individuals.
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EXPERIMENTAL PROCEDURES
Materials. Human recombinant insulin (I9278), Collagen (Type I, C3867),
phosphate-buffered saline pH 7.4 (PBS) and Leptomycin B (L2913) were
purchased from Sigma. HALT phosphatase inhibitor cocktail was from Pierce,
and Complete protease inhibitor cocktail was from Roche. Antibodies to: HA
(Covance and Santa Cruz), Foxa1 (a gift from J. Darnell, Rockefeller
University; or from Abcam, ab23738), rabbit or goat polyclonal to Foxa2
(Abcam), phosphorylated Foxa2 (T156) antibody was generated and described
previously (Cell Signaling) (10), LSD1 (Cell Signaling), GAPDH (Abcam),
Orexin A (Abcam, ab35337), pro-MCH (Santa Cruz, sc-14509) gamma tubulin
(Sigma), AKT (Cell Signaling), Foxo1 (Santa Cruz), TAF100 (a gift from R.G.
Roeder, Rockefeller University), SUMO-1 (Zymed, 38-1900).

Animal Models.
River.

C57BL/6 and ob/ob mice were purchased from Charles

All animals were maintained on a normal chow diet and a 12 h

light/dark cycle. All mutant animals were crossed to a C57Bl/6 background.
Diet induced obese animals were fed a high fat diet (Harland Teklad)
containing 50% fat for 12 weeks. Gestation was dated by detection of the
vaginal

plug,

which

was

considered
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gestational/embryonic

day

1.

Sreptozotocin-induced diabetes was initiated on gestational day 14; mice were
given 3 injections of 75 mg/kg stz over 3 days.

Generation of FOXA2 T156A knock-in mice. FOXA2T156Afllox/flox mice
were generated using a targeting construct. The short arm spanning exon 1 and
2 (3.4 kb in length) from bp position -2517 to +919, relative to the translation
start site (+1). The long arm, which contained exon 3 with the T156A mutation
was 4.7 kb in length from bp position +1034 to +5782, relative to the
translation start site. Wild type exon 3 was located between the long and short
arm and flanked by a loxP sequence. A neo/tk cassette, flanked by loxP sites,
was inserted upstream of wild type exon 3. An outside probe was used to
visualize homologous recombination and Cre recombination events. The
targeting vector was electroporated into R1 ES cells from mouse strain 129
(Nagy et al., 1993) and neomycin-resistant colonies were recovered. The
colonies were screened by Southern blotting using probe 1 and positive
colonies were confirmed by Southern blotting with a probe located
downstream of the 3’ homology arm. To delete the neo/tk-cassette from the
targeted allele, recombinant ES clones were transiently transfected with a
plasmid expressing Cre-recombinase. ES clones with partial recombination and
deletion of the neo/tk cassette were injected into B6(D2B6F1) blastocysts to
produce chimeric mice. Germline transmission was confirmed by Southern
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blotting. FOXA2T156Aflox/flox mice were first backcrossed for 7 generations to
C57Bl/6J mice. To obtain brain-specific FOXA2T156A knock-in mice,
FOXA2T156Aflox/flox mice were bred to Nestin-Cre mice (B6.Cg-Tg(Nescre)1Kln/J, Jackson Laboratories) (14), which had been backcrossed to
C57Bl/6J for at least 6 generations. To confirm expression of the Foxa2T156A
allele, Foxa2T156A transcripts were amplified from brain and liver using
primers

spanning

one

intron

of

the

mouse

(AGCGGCCAGCGAGTTAAAGTATGC

Foxa2

gene
and

CTGCCGGTAGAAAGGGAAGAGGTC). RT-PCR products were cloned
into the TOPO3 vector (Invitrogen) and sequenced.

Plasmids and Adenovirus. HA-tagged Foxa2, Foxa2-T156A, and Akt2 were
in PCDNA3 expression vectors as previously described (36). Emut (L110A,
L113A) and TAE (L110A, L113A, T156A) constructs were generated by sitedirected mutagenesis using overlap extension PCR.

Adenoviruses were

generated using the Rapid Adenovirus Production System (Viraquest). With the
exception of Ad-GFP-C1Foxa2, GFP was coexpressed from an independent
promoter in addition to HA-Foxa2 or Foxa2 variants. Ad-GFP, Ad–Foxa2 and
Ad–T156A were described previously (10). For in vivo experiments, mice were
injected with 8x108 PFU of adenovirus through the tail vein.
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Cell culture.

HepG2 cells and primary hepatocytes were maintained on

collagen-coated plates in DMEM (Gibco, containing 4.5 g/L glucose, 110
mg/L sodium pyruvate, 4 mM L-glutamine) supplemented with 10% fetal
bovine serum (Sigma) and 100 U/mL penicillin/ streptomycin, in a humidified
incubator at 37°C and 5% CO2. Serum starvation was carried out for 18 h in
DMEM without FBS and Pen/Strep.

Stable cell lines were generated by

transfection of 4.5x106 HepG2 cells with 6 μg of plasmid DNA using Fugene6
transfection reagent (Roche), and selection with 1 mg/mL of G418
(Calbiochem) over 2-3 weeks. Clonal populations were isolated and analyzed
for expression of Foxa2 constructs by western blotting using an anti-HA
antibody (MMS-101P, Covance).

Primary Hepatocytes. Mice were anesthetized with pentobarbital. A catheter
(24 gauge) was inserted into the portal vein, and the liver was perfused with a
buffer containing 10 mM HEPES (pH 7.4), 143 mM NaCl, 7 mM KCl, and 0.2
mM EDTA at a flow rate of 1 ml/min. Effluent exited via the vena cava
inferior. After 10 ml of perfusion, the buffer was switched to a collagenase
buffer (50 mM HEPES (pH 7.4), 100 mM NaCl, 7mM KCl, 5mM CaCl2, and
0.2% collagenase type IV (Sigma)). After 6 ml of perfusion, the liver was cut
out and minced in Dulbecco’s modified Eagle’s medium (with 10% fetal bovine
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serum) containing 4.5 g/liter glucose. Hepatocytes were released from the liver
during 15 min of light shaking at 37 °C. The cell suspension was filtered
through a 40 μm nylon mesh cell strainer (BD Falcon) and centrifuged at 80 x g
to pellet the hepatocytes. The cell pellet was washed three times with warm
media, and the cells were plated onto collagenized plates. Cells were allowed to
attach for 6 h after which cells were washed and medium was changed.

Whole Cell Extracts. From HepG2 cells: Cells were washed, scraped and
centrifuged at 500 x g for 5 m at 4°C in cold 0.01 M PBS. The cell pellet was
then resuspended in whole cell extract buffer (150 mM NaCl, 50 mM Tris pH
7.4, 5 mM EDTA, 0.1% SDS, and complete protease inhibitor (Roche)). The
soluble fraction was collected after centrifugation at 13,000 rpm for 5 m at 4°C.
A two-step lysis was used for tissue whole cell extracts: tissues were dounced
10-15x with a tight pestle in cold buffer A (10 mM HEPES pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.6% NP40) containing 1.67x phosphatase inhibitor
cocktail (Pierece HALT) and 1.67x protease inhibitor cocktail (Complete
mixture Roche Applied Science) and incubated on ice for 10 m. Lysates were
then vortexed for 5 s, followed by dropwise addition of 140 μL of buffer B (1.2
M NaCl, 20 mM Hepes pH 7.9, 0.2 mM EDTA, 1.5 mM MgCl2, 25%
glycerol;without additives) and overhead rotation for 40 m at 4°C to ensure
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lysis. Insoluble cellular components were removed by centrifugation at 16,000
x g for 30 m at 4°C, and the supernatant was collected.

Protein measurement. In all cases, protein concentrations were determined
bicinchoninic acid (BCA) assay using a bovine serum albumin standard curve
prepared in the cell lysate buffer. (In the case of buffers containing DTT the
standard curves were always made fresh for most accurate quantitation).

Nuclear Fractionation.

Initial nuclear extraction experiments were by

sucrose gradient fractionation. Tissues were dounced 20x in homogenization
buffer (10 mM Hepes pH 7.9, 25 mM KCl, 2 M Sucrose, 10% glycerol, 1 mM
EDTA) containing protease inhibitor cocktail (added fresh). Homogenates
were carefully layered over a 1 cm cushion of homogenization buffer in SW55
ultracentrifugation tubes (Beckman) and centrifuged at 100,000 x g (29,000
RPM in SW55) for 40 minutes at 4°C. Supernatant was carefully removed by
pipetting and discarded, and nuclear pellets were resuspended in 2 mL of
nuclear lysis buffer (10 mM Hepes pH 7.9, 100 mM KCl, 3 mM MgCl2, 0.1
mM EDTA) containing 1 mM DTT and protease inhibitor cocktail (added
fresh). Nuclear lysates were incubated on ice for 20 minutes, followed by the
addition of 0.1 volume (NH4)2SO4 over 30 m to precipitate chromatin, and
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centrifuged at 100,000xg (29,000 RPM) for 60 min at 4°C. The supernatant
was collected and 0.66 g of (NH4)2SO4 was added over 15 m to precipitate
protein, which was pelletted by centrifugation for 30 minutes at 100,000g at
4°C and resuspended in nuclear resuspension buffer (25 mM Hepes pH 7.4, 40
mM KCl, 0.1 mM EDTA, 10% (v/v) glycerol) containing 1mM dTT (added
fresh). Protein was dialyzed overnight against 3 x 2 L of nuclear resuspension
buffer.

Nuclear/Cytosoplasmic Extracts. HepG2 cells were grown in 10 cm plates
to 80% confluency and serum-starved for 18 h, followed by the indicated
treatments (LMB: 2 h with 2.5 ng/mL leptomycin B, Insulin: 500 nM human
recombinant insulin for 15 min at 37°C). Nuclear and cytoplasmic extracts
were prepared as previously described (23). Briefly, cells were swollen on ice in
hypotonic lysis buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl)
containing 1 mM dithiothreitol and protease inhibitors (Complete mixture,
Roche Applied Science), and permeabilized by the addition of NP40 to 0.6%.
After centrifugation at 10,400xg for 30 sec at 4°C, the supernatants
(cytoplasmic extracts) were collected, and nuclear pellets were resuspended in
nuclear lysis buffer (10 mM HEPES pH 7.9, 100 mM KCl, 3 mM MgCl2, 0.1
mM EDTA) containing 1 mM dithiothreitol and protease inhibitors. Nuclei
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were lysed by the gradual addition of one-tenth volume of 4 M (NH4)2SO4 over
30 min.

For liver experiments, ~50 mg of liver was dounced directly in

hypotonic lysis buffer on ice, 10x with a tight pestle.

Quantification of Cytosolic and Nuclear Foxa2.

Western blots were

scanned and band intensity quantified by densitometry using Kodak imaging
software. Each value was normalized to the corresponding γ-tubulin value. To
account for differences in blotting and exposure, each blot contained the same
standard, and all values were adjusted to the intensity measured for this
standard.

Transfection and Transactivation assays.

HepG2 cells were plated at

70,000 cells per well in 24-well plates and transfected the following day with 25
ng p6xCdx-TkLuc reporter gene (36), 10 ng pRL-Tk, and 25 ng of Foxa2
expression vectors alone or in combination with 5 ng of a human Akt2
expression vector using Lipofectamine 2000 (Invitrogen). Cells were harvested
40 h post-transfection and luciferase was measured using the Dual Luciferase
System (Promega) according to manufacturer’s protocol on a Promega GloMax
luminometer.
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Immunofluorescence Microscopy. Liver pieces were frozen directly in OCT
(optimal cutting temperature) compound at –80°C. 9 μM cryosections were
fixed in 4% paraformaldehyde in 0.01 M PBS at 4°C for 30 min, permeabilized
in 0.2% NP40 in PBS, blocked in 5% NDS, 1% BSA, 0.1% NP40 in PBS, and
incubated with anti-HA antibody (1:25, Santa Cruz Biotechnology, sc-805)
overnight at 4°C in a humidified chamber. Donkey anti-rabbit IgG Alexa Fluor
488 (Molecular Probes) was used as a secondary antibody, and mounted with
VECTASHIELD mounting media with Dapi (Vector Labs) to visualize nuclei.
For hypothalamus staining, mice were CO2-anesthesized and intracardially
perfused with 5 ml of phosphate-buffered 2% paraformaldehyde (pH 7.4).
Brains were postfixed in phosphate-buffered 2% paraformaldehyde (pH 7.4)
for 10 minutes at room temperature, equilibrated in phosphate-buffered 30%
sucrose at + 4O C for 24 hours and frozen in tissue-tek OCT compound
(Sakura). Brains were cryo-sectioned into 12μm thick coronal sections, which
were stored at -20 °C until further use. Cryosections were permeabilized for 1 h
at room temperature in 10mM PBST (10 mM PBS, pH 7.4, 0.1%-Triton X100), blocked with 1% BSA, 5% serum in PBST for 1 h at room temperature
and incubated overnight at 4 °C with the primary antibody at a 1:50 - 1:300
dilution in 1% BSA, 5% serum in PBST. After three washes, sections were
incubated for 1 h at room temperature with secondary antibodies (Alexa Fluor
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488 or Alexa Fluor 568 conjugated; Molecular Probes, Invitrogen) diluted 1:500
in 1% BSA, PBST. Immunofluorescent staining was visualized with a Leica
confocal microscope at 40x magnification.

Immunoprecipitation. Primary hepatocytes from three wildtype C57Bl/6
mice were pooled and plated onto ten 10 cm collagen-treated plates. Cells were
washed extensively and allowed to recover over 48 h, after which they were
infected with 2.5x107 PFU of the indicated virus. After an additional 24 h, cells
were serum-starved overnight, followed by 15 min stimulation in the absence
or presence of 100 nM insulin. Cells were washed twice in cold 0.01 M PBS
(containing 10mM NaF, and 0.5X HALT phosphatase inhibitor cocktail from
Pierce) and moved directly to ice, scraped and centrifuged at 500 x g for 5 m at
4°C. Cell pellet was resuspended in 200 μL of buffer A (10 mM HEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.6% NP40) containing 1.67x phosphatase
inhibitor cocktail (Pierece HALT) and 1.67x protease inhibitor cocktail
(Complete mixture Roche Applied Science). Incubated cells on ice for 10 m,
vortexed 5 s, followed by dropwise addition of 140 μL buffer B (1.2 M NaCl,
20 mM Hepes pH 7.9, 0.2 mM EDTA, 1.5 mM MgCl2, 25% glycerol) without
additives. Rotated (overhead) 40 m at 4°C to ensure lysis. Centrifuged at
16,000 x g for 30 m at 4°C to pellet chromatin and debris, and collected
supernatant as whole cell lysate. Brought 120ug of protein lysate up to 276 μL
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with A/B lysis buffer (mixed 1.5:1), added 600 μL IP buffer (0.01 M PBS pH
7.4, .01 mM EDTA, 0.02% NP40) containing phoshpatase and protease
inhibitor) to each and subjected all to immunoprecipitation overnight at 4°C
with monoclonal HA agarose (Sigma A2095) in SigmaPrep spin columns.
Washed 5 x 800 μL with IP buffer containing 10 mM NaF. Centrifuged 1 m
at 1000xg to remove excess liquid, plugged columns and added 60 μL 1X laemli
buffer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1 mM bromophenol blue)
to elute.

Chromatin Immunoprecipitation. Primary hepatocytes from three wildtype
C57Bl/6 mice were pooled and plated onto ten 10 cm collagen-treated plates.
Cells were washed extensively and allowed to recover over 48 h, after which
they were infected with 2.5x107 PFU of the indicated virus. After an additional
24 h, cells were serum-starved overnight, followed by 15 min stimulation in the
absence or presence of 100 nM insulin. 11X fixing solution (50mM HepesKOH pH 7.5, 100mM NaCl, 1mM EDTA pH 8.0, 0.5mM EGTA p H8.0, 11%
formaldehyde) was added to the cells to a final concentration of 1X and
incubated for 10 min at 37°C. Cells were then moved to ice, washed twice with
ice cold 0.01 M PBS and scraped in 1 mL ChIP cell lysis buffer (10 mM Tris–
Cl, pH 8.0, 10 mM NaCl, 1.5 mM MgCl2, 0.2% NP-40, with protease
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inhibitors). Lysates were centrifuged for 5 min at 5400xg at 4°C. Pellets were
resuspended in 450 μL of SDS Lysis buffer (Upstate Biotechnology) and
sonicated 4x20 sec on, 30 sec off, at amplitude 16 on a Misonix Sonicator 4000.
Lysates were further processed according to the manufacturers protocol
(Chromatin immunoprecipitation assay kit, Upstate Biotechnology).

DNA

complexes were immunoprecipitated overnight using 2.6 μg of HA-antibody
(Santa Cruz Biotechnology, sc-805) or rabbit IgG (ChromPure, Jackson
ImmunoResearch). Primer sequences are given in Table 5.
Table 4. Primer Sequences and annealing temperatures for ChIP.
Primer
Forward Sequence
Reverse Sequence
Name
CPT1α
AAGGCATACATCACCACAACCAGT TTCACAACAACACTGTGGTGTGC
Gck
TCTCCACACCAGCTTGGAACC
TTTCACCACCATCAGTATGCAC
HMGCS1
TGCACTGTTCCTGGCTGGTATCTA TGATTGTTGGATGTGTTAGAAGGA
TCTCTATTGAAGCTGATGGACTG
AGTCCCCACATCTTCCCTTCC
LPK
PEPCK
ATACGTACATACTGACCCCTGCTC GATCATCAGAGTTCCATTTCAAGA

Ta
(°C)
57
57
57
57
57

Gene Chip. Adult lung RNA was prepared from 5 fasted and 5 fed mice by
Trizol extraction, pooled and purified using RNEasy columns (Qiagen). RNA
was then submitted to the functional genomics center (ETH Zurich) for
labeling and hybridization. Whole snap-frozen embryonic lungs from two
fetuses of stz-induced diabetic mothers, and two from fasted mothers were
submitted to Miltenyi for RNA extraction, labeling, and hybridization onto a
one-color 4x44K Agilent genechip.

Data was analyzed using Genespring

software.
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Gene Expression. Total RNA was extracted from lung tissue using TRIzol
reagents following the manufacturer’s instructions (Invitrogen). Contaminating
genomic DNA was removed by a 3 hour DNase I treatment (Ambion). RNA
quality was confirmed by denaturing gel electrophoresis stained with ethidium
bromide. cDNA was synthesized using Superscript III with random hexamer
primers and oligo dT according to the manufacturer’s protocol (Invitrogen).
Combined extraction of mRNA and cDNA synthesis were performed from 50
mg of liver tissue with the μMACS One-step cDNA Kit (Miltenyi Biotec)
following the manufacturer's protocol, with an additional 10 minute RNase-free
DNase I treatment (NEB). Gene expression was measured quantitatively as a
function of SYBR green incorporation during PCR using gene-specific exonspanning primers, LightCycler 480 SYBR Green I Master mix (Roche) and the
Mx3005P Real-Time QPCR Detection System (Stratagene). Values shown are
given in arbitrary units based on a standard curve, and normalized to GAPDH.
Primer sequences are given in Table 5.
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Table 5. Primer sequences and annealing temperatures for real-time PCR.
Primer
Forward Sequence
Reverse Sequence
Name
Apq3
GCTGGGATTGTTTTTGGGCTGTAC
GCGGCTGTGCCTATGAACTGATC
CCSP
TCACTGTGGTCATGCTGTCCATCT
TGAAAGGCTTCAGGGATGCCACAT
CPT1α
AGCGACTCTTCAATACTTCCCGCA
TCTGTGGTACACGACAATGTGCCT
AAGTATGCTGGGAGCCGTGAAGAT
CGCGGACATGCTCATGTATGTGTT
Foxa2
GAPDH
CTGACGTGCCGCCTGGAGAAA
CCGGCATCGAAGGTGGAAGA
ACCTGTAGGTCTGGCATTTCCTGT
HMGCS1 AATCCAGCTCTTGGGATGGACGAT
MCAD
AGTACCCGTTCCCTCTCATCAA
TACACCCATACGCCAACTCTTC
TGCACCTGGAGAACATGGAGACAA
ATGGATCCTTGCAAGCTGAGGACT
SP-A
SP-B
CCTGCCCCTGGTTATTGACTACTTC
GCAGCACAGGGAGGACCAG
AGGAGCCGCTGGTAGTCATA
SP-C
CGCCTTCTCATCGTGGTTGT
VLCAD
GGTTACCCATGGGCTCCCTGAAAAG
TTGAAGCCATCTCCCACCTCTCCTA
Orexin
CTGCCGTCTCTACGAACTGTTG
CGCTTTCCCAGAGTCAGGATA
MCH
TTCAGAAGGAAGATACTGCAGAAAGA CGCTCTCGTCGTTTTTGTATTG
β-actin
GAGAAGCTGTGCTATGTTGCTC
AGGAAGAGGATGCGGCA

Ta
°C
63
63
63
60
63
63
60
63
63
63
60
60
60
60

Immunoblotting. Protein extracts were separated by SDS-PAGE (10%) and
transferred onto nitrocellulose membranes (Perkin Elmer) by electroblotting.
Membranes were immunoblotted according to standard protocols using 5%
non-fat dry milk in TBST. Blots were stained with Ponceau S to ensure equal
loading and incubated with primary antibodies overnight at 4 °C (rabbit antiHA 1:500; rabbit anti-Foxa2 (Abcam) 1:10,000; all others were at 1:1000).
Secondary antibody was added for 1 h at room temperature (1:10,000;
Calbiochem).

Antibody Production. Rabbit polyclonal antibody to Foxa2 was generated by
injection of GST-purified Foxa2 (Bethyl) and affinity purified over a GSTFoxa2 column.
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Physiological measurements. Retro-orbital blood samples were taken into
non-heparinized capillary tubes. Blood glucose was measured using a standard
glucometer (Ascensia Contour, Bayer). Plasma insulin was measured with the
Sensitive Rat Insulin RIA kit (Linco Research).

Liver triglycerides were

extracted by the Folch method and quantitated by colorimetric assay (Roche).
Plasma cholesterol and plasma triglycerides were measured by colorometric
assay (Roche).

Metabolic Measurements. Locomotion (x-, y- and z-axis), food and water
intake, oxygen consumption, CO2 and heat production were simultaneously
determined for four mice in separate cages per experiment during a 24 h period
in an Oxymax metabolic chamber system (Columbus Instruments) at the ages
of 4 and 8 weeks.

Mitochondrial isolation. Mitochondria were isolated as previously described
(121). 200 mg of PBS-perfused mouse livers were dounced in 4 volumes of
MSM buffer (220 mM mannitol, 70 mM sucrose, 5 mM Mops pH 7.4) 4 x with
a loose pestle. The homogenate was diluted with MSM buffer to a final tissue
concentration of 10% , and EDTA was added to 2 mM. Nuclei, unbroken
cells, and cell debris were removed by differential centrifugation at 400 x g for
10 m.

Mitochondria were isolated from the supernatant by additional
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centrifugation at 7000 x g for 10 m and washed once with MSM buffer.
Mitochondrial pellets were resuspended in a small volume (20 μL) MSM buffer,
and normalized to protein concentration.

Beta Oxidation/Ketone Body Formation. We assessed the β-oxidation of
and ketone body production from [1-14C]palmitic acid by liver mitochondria in
samples normalized to mitochondrial protein, as described (122). 1 mg of
mitochondrial protein was brought up to 360 μL with preincubation medium
(70 mM sucrose, 43 mM KCl, 3.6 mM MgCl2, 7.2 mM KH2PO4, 36 mM TrisHCl pH 7.4, 0.2 mM adenosine triphosphate, 50 μM L-carnitine, 15 μM
CoASH) and incubated for 5 m at 37 °C. 40 μL of incubation media (400 μM
[1-14C]palmitic acid (0.4 μCi/40 μL), 2.5 mg/mL BSA) was then added and
tubes were closed with Whatman paper-lined caps soaked in 100 mM NaOH
and incubated for 30 m at 37 °C with in a water bath shaking at 85 RPM. The
reaction was stopped by adding 100 μL of 5% perchloric acid to the incubation
mixture, and further incubated for 60 m at 37 °C with gentle shaking. CO2
trapped on the filter papers was counted for 14C activity by scintillation counter.
To measure ketone body formation, the incubation mixture was centrifuged at
4,000xg for 10min, and 14C acid-soluble products of mitochondrial palmitate
metabolism were counted from an aliquot (200 μL) of the supernatant.
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Statistical Analysis.

Results are given as mean ± SEM, if not otherwise

indicated. Statistical analyses were carried out by using a two-tailed Student’s
unpaired t test, and the null hypothesis was rejected at the 0.05 level. *, p <.05;
**, p<.01, ***, p<.001
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